SEARCH
検索詳細平林 真介 (ヒラバヤシ シンスケ)
| 北海道大学病院 小児・周産・女性科 | 助教 |
研究者基本情報
■ 学位■ URL
researchmap URLホームページURL■ ID 各種
J-Global ID■ 研究キーワード・分野
研究分野■ 担当教育組織
研究活動情報
■ 論文- Therapeutic Courses of Presumed Intracranial Immature Teratoma Diagnosed Based on Increased Alpha-Fetoprotein.
Shigeru Yamaguchi; Yukitomo Ishi; Michinari Okamoto; Sogo Oki; Ryosuke Sawaya; Hiroaki Motegi; Yukayo Terashita; Shinsuke Hirabayashi; Kentaro Nishioka; Takayuki Hashimoto; Hiromi Okada; Emi Takakuwa; Hidefumi Aoyama; Atsushi Manabe; Miki Fujimura
Journal of child neurology, 8830738261446144, 8830738261446144, 2026年05月07日, [国際誌]
英語, 研究論文(学術雑誌), Intracranial immature teratoma (ImT) is one of the non-germinomatous germ cell tumors, and elevated serum alpha-fetoprotein (AFP) value is a crucial clinical diagnostic indicator of ImT. In this retrospective study conducted among patients diagnosed with intracranial ImT, diagnostic procedures, therapeutic courses, histopathologic diagnosis, and prognosis were reviewed. Among 106 patients with intracranial germ cell tumors, 11 were diagnosed with ImT and treated since 2000. ImT was diagnosed via biopsy or based on mild or moderate serum AFP elevation of 10-500 ng/mL. Complete remission via chemoradiotherapy was achieved in only 2 patients (18%); 5 patients (45%) suffered from growing disease during treatment; and 7 patients required salvage tumor resection. The 10-year progression-free and overall survival rates were 76.2% and 87.5%, respectively. The therapeutic courses of ImT varied. Notably, cases in which treatment was applied considering ImT were highly prone to experience growing disease during treatment. - Endocrine disorders in pediatric medulloblastoma survivors treated with X-ray or proton beam therapy: a single-institution retrospective study.
Naoya Kaneko; Shuntaro Morikawa; Megumi Endo; Nozomi Hishimura; Liu Zhitong; Takeshi Yamaguchi; Hisato Segoe; Jutaro Abe; Kazumi Oura; Saori Sawai; Minako Sugiyama; Yukayo Terashita; Shinsuke Hirabayashi; Yuko Cho; Akie Nakamura; Yukitomo Ishi; Seishin Takao; Yuto Matsuo; Shigeru Yamaguchi; Takayuki Hashimoto; Atsushi Manabe
Endocrine journal, 2026年04月10日, [国内誌]
英語, 研究論文(学術雑誌), Medulloblastoma, a common pediatric central nervous system disease, is managed with surgery, chemotherapy, and craniospinal irradiation (CSI) delivered with either X-rays or protons. Proton-beam CSI, introduced to protect the surrounding tissues, may reduce endocrine toxicity. In this single-institution retrospective observational study, we evaluated adverse endocrine events in 14 patients diagnosed with medulloblastoma before 13 years of age: 9 and 5 received X-ray and proton beam CSI, respectively. In the X-ray therapy group, the median age at diagnosis was 4.2 (range: 1.4-12.5) years, the median post-radiation follow-up was 19.5 (9.7-34.7) years, and the median CSI dose was 25.2 (23.4-36.0) Gy. The proton beam therapy group showed corresponding medians of 9.4 (5.3-11.7) years, 6.9 (5.4-8.1) years, and 23.4 (23.4-36.0) Gy. Five years after radiation therapy completion, the incidence of growth hormone deficiency was 44% (4/9) and 60% (3/5) in the X-ray and proton beam therapy groups, respectively. However, primary hypothyroidism and central hypothyroidism were exclusively observed in the X-ray therapy group, in 33% (3/9) and 11% (1/9) of patients. Given the short follow-up period for the proton beam therapy group, the difference in the occurrence rates of gonadal dysfunction and adrenal insufficiency is currently unknown. Our findings suggest that, at ≤5 years after the completion of radiation therapy, radiation-induced hypothyroidism was observed only in patients treated with X-ray therapy and not in those treated with proton beam therapy. Further studies with larger cohorts and longer follow-up periods are required to clarify this possible advantage and to refine radiation therapy protocols. - Endocrine dysfunction induced by anti-PD-1 antibody and tyrosine kinase inhibitor in a pediatric patient with renal cell carcinoma
Megumi Endo; Shuntaro Morikawa; Naoya Kaneko; Nozomi Hishimura; Liu Zhitong; Takeshi Yamaguchi; Atsushi Yamaguchi; Hisato Segoe; Jutaro Abe; Kazumi Oura; Yukayo Terashita; Yuko Cho; Shinsuke Hirabayashi; Atsushi Manabe
Clinical Pediatric Endocrinology, Japanese Society for Pediatric Endocrinology, 2026年
研究論文(学術雑誌) - Comprehensive Cancer Genomic Profiling and Germline Predisposition Analysis in Pediatric Cancer: Insights From the Hokkaido Pediatric Cancer Consortium, Japan
Yusuke Saito; Yukayo Terashita; Toraji Amano; Minako Sugiyama; Kazumi Oura; Masataka Hasegawa; Jutaro Abe; Shinsuke Hirabayashi; Yuko Cho; Shin Ariga; Kanako Hagio; Yoshihito Ohhara; Junko Kikuchi; Yukitomo Ishi; Shigeru Yamaguchi; Hiromi Kanno-Okada; Emi Takakuwa; Zen-Ichi Tanei; Yuka Shibata; Mio Mukainakano; Honami Fujita; Kanako C. Hatanaka; Yutaka Hatanaka; Akira Takebayashi; Yusuke Akane; Masaki Yamamoto; Takeo Sarashina; Shinya Tanaka; Takahiro Yamada; Ichiro Kinoshita; Atsushi Manabe
PEDIATRIC BLOOD & CANCER, 72, S850, S850, 2025年12月
英語 - The Safety and Efficacy of Ruxolitinib in an Infant With Familial Hemophagocytic Syndrome Type 3: A Bridging Therapy Toward Hematopoietic Cell Transplantation and Treatment of Post-Transplant Complications, Including Sinusoidal Obstruction Syndrome.
Kazuki Takahashi; Shinsuke Hirabayashi; Masahiro Ueki; Masataka Hasegawa; Hiroki Ohata; Shunichiro Takezaki; Yukayo Terashita; Yuko Cho; Atsushi Manabe
Pediatric blood & cancer, e32073, 2025年09月24日, [国際誌]
英語 - Post-Transplant Course of Pearson Syndrome.
Miki Murakoshi; Miho Ashiarai; Shinsuke Hirabayashi; Akira Nishimura; Rintaro Ono; Hiroki Yoshihara; Yosuke Hosoya; Atsushi Manabe; Miwa Ozawa; Daisuke Hasegawa
Pediatric blood & cancer, 72, 7, e31736, 2025年07月, [国際誌]
英語 - Pediatric Pulmonary Hypertension Associated With Treatment of Myeloproliferative Disorders and Malignant Tumors.
Ayako Chida-Nagai; Yukayo Terashita; Shinsuke Hirabayashi; Hirokuni Yamazawa; Yuko Cho; Atsushi Manabe
Pulmonary circulation, 15, 3, e70165, 2025年07月, [国際誌]
英語, 研究論文(学術雑誌), Pulmonary hypertension (PH) is a severe complication observed in pediatric patients after hematopoietic cell transplantation or chemotherapy. A review of records at Hokkaido University Hospital (2014-2024) identified four cases of PH, each with different etiologies, including pulmonary arterial hypertension, pulmonary veno-occlusive disease, and microthromboembolism. Contributing factors included splenic atrophy, corticosteroid-responsive inflammation, and potential drug-induced vascular remodeling. Although transient PH usually resolves, late-onset PH emphasizes the need for long-term echocardiographic monitoring. These findings underscore the importance of individualized management, avoiding pulmonary vasodilators without proper evaluation, and addressing underlying conditions such as thrombotic microangiopathy or interstitial lung disease. - Near-infrared photoimmunotherapy using antiGD2 antibody for neuroblastoma and osteosarcoma
Jimei Zhao; Kohei Nakajima; Masahiro Ueki; Yukayo Terashita; Shinsuke Hirabayashi; Yuko Cho; Mikako Ogawa; Atsushi Manabe
EJC Paediatric Oncology, 5, 100233, 100233, Elsevier BV, 2025年06月
研究論文(学術雑誌) - Ultrasonographic scoring system for SOS/VOD in pediatric hematopoietic stem cell transplant recipients.
Mutsumi Nishida; Shinsuke Hirabayashi; Takahito Iwai; Megumi Sato; Yusuke Kudo; Satomi Omotehara; Tatsunori Horie; Ryosuke Sakano; Yukayo Terashita; Yuko Cho; Atsushi Manabe; Takanori Teshima
International journal of hematology, 2025年04月26日, [国内誌]
英語, 研究論文(学術雑誌), Sinusoidal obstruction syndrome (SOS)/veno-occlusive disease (VOD) is a serious complication following hematopoietic stem cell transplantation. It is more common in children, with an incidence of approximately 20% compared to 10% in adult patients. While the Hokkaido ultrasonography (US)-based scoring system (HokUS-10 and HokUS-6) has proven effective in diagnosing SOS/VOD in adults, its utility in children remains uncertain. This study evaluated the utility of the HokUS-10/6 scoring systems in diagnosing pediatric SOS/VOD (pSOS/VOD) in a cohort of 99 patients, including 13 diagnosed with pSOS/VOD. Hyperbilirubinemia (> 2 mg/dL) was observed in only three patients (23%), whereas transfusion-refractory thrombocytopenia, hepatomegaly, and ascites were observed in all 13 patients. When the cutoff values for HokUS-10 and HokUS-6 scores were set at 4 and 2, the respective areas under the curve were 0.977 and 0.957. The sensitivity and specificity were 100% and 80% for HokUS-10, and 77% and 97% for HokUS-6, respectively. The simplified HokUS-6 may be a practical tool for diagnosing pSOS/VOD when use of the HokUS-10 scoring system is not feasible. HokUS-10/6 is important for early detection of pSOS/VOD during regular examinations and plays a valuable role in the diagnosis of clinical pSOS/VOD. - Mature teratoma with a germinoma component presenting with undetectable placental alkaline phosphatase in cerebrospinal fluid: illustrative case.
Sogo Oki; Shigeru Yamaguchi; Michinari Okamoto; Yukitomo Ishi; Hiromi Kanno-Okada; Emi Takakuwa; Yukayo Terashita; Shinsuke Hirabayashi; Kentaro Nishioka; Takayuki Hashimoto; Atsushi Manabe; Miki Fujimura
Journal of neurosurgery. Case lessons, 9, 8, 2025年02月24日, [国際誌]
英語, 研究論文(学術雑誌), BACKGROUND: Diagnosing intracranial mixed germ cell tumors (GCTs) can be challenging due to intratumoral heterogeneity. Placental alkaline phosphatase (PLAP) in the cerebrospinal fluid (CSF) is a highly sensitive and specific marker for identifying pure germinomas and germinoma components within mixed GCTs. OBSERVATIONS: The authors present the case of a 6-year-old boy presenting with a 5-day history of vomiting and headache. Magnetic resonance imaging revealed a heterogeneously enhanced mass with cystic areas in the pineal region. Preoperative serum levels of alpha-fetoprotein and human chorionic gonadotropin, as well as CSF PLAP levels, were not elevated, leading to a preliminary diagnosis of mature teratoma. The tumor was completely resected, and pathological examination of the resected tissue confirmed a mature teratoma with germinoma components. Given the diagnosis of mixed GCT with a germinoma component, the patient underwent postoperative radiation chemotherapy. There has been no recurrence after 8 years of follow-up. LESSONS: In this case, the preoperative CSF PLAP level failed to predict the presence of a germinoma component. This report highlights a potential limitation of CSF PLAP as a diagnostic marker, noting that CSF PLAP may be undetectable if the germinoma is confined to a localized area. https://thejns.org/doi/10.3171/CASE24588. - Comparison of busulfan pharmacokinetics between four-times-daily and once-daily administration in pediatric patients: a preliminary prospective observational trial
Atsushi Yamaguchi; Shinsuke Hirabayashi; Kazuko Niki; Keisuke Kagami; Yukayo Terashita; Yuko Cho; Atsushi Manabe; Mitsuru Sugawara; Yoh Takekuma
International Journal of Hematology, Springer Science and Business Media LLC, 2024年12月03日
研究論文(学術雑誌) - Increased response to granulocyte-macrophage colony-stimulating factor in peripheral blood cells and transient manifestations mimicking juvenile myelomonocytic leukemia in a male patient with NEMO deficiency caused by a deep intronic pathogenic variant of IKBKG.
Masahiro Ueki; Shinsuke Hirabayashi; Yoshitaka Honda; Shunichiro Takezaki; Hiroki Ohata; Shimaa Said Mohamed Ali Abdrabou; Saori Sawai; Yukayo Terashita; Yuko Cho; Hideki Muramatsu; Kazushi Izawa; Takahiro Yasumi; Yoshiyuki Takahashi; Masafumi Yamada; Atsushi Manabe
Immunological medicine, 1, 8, 2024年11月01日, [国際誌]
英語, 研究論文(学術雑誌), X-linked NF-κB essential modulator (NEMO) deficiency is a primary immunodeficiency characterized by combined immunodeficiency and ectodermal dysplasia. Monocytes from the patients demonstrate a severely impaired response to tissue necrosis factor or lipopolysaccharide, whereas hyper-inflammation is found in some patients. Juvenile myelomonocytic leukemia (JMML) is a pediatric malignancy caused by hypersensitivity to granulocyte-macrophage colony-stimulating factor (GM-CSF) and aberrant RAS signaling activation. Patients with JMML demonstrate characteristic manifestations such as splenomegaly, monocytosis and the presence of myeloid or erythroid precursors in the peripheral blood. Here, we present the case of a male infant with ectodermal dysplasia, bacterial septicemia, Pneumocystis pneumonia, severe inflammation and transient manifestations mimicking JMML. Genetic analysis revealed a deep intronic germline variant of IKBKG. Full-length IKBKG cDNA and NEMO protein expression were almost inexistent. Peripheral mononuclear cells (PBMCs) from the patient showed increased RAS signaling activation with GM-CSF or Phorbol 12-myristate 13-acetate without the RAS-associated gene variant, although the increased RAS signaling activation in induced-pluripotent stem cell-derived myeloid lineage and bone marrow-derived mesenchymal cells was not evident. The patient with NEMO deficiency demonstrated JMML-like manifestation and severe inflammation. PBMCs of the patient demonstrated increased RAS signaling activation with unknown pathophysiology. - Sunburst appearanceを呈する頭蓋骨腫瘤を契機に発見された神経芽腫の1例
北川 悠; 竹中 淳規; 渡邊 史郎; 平田 健司; 内山 裕子; 木村 理奈; 中川 純一; 池辺 洋平; 工藤 與亮; 長谷河 昌孝; 澤井 彩織; 寺下 友佳代; 杉山 未奈子; 平林 真介; 長 祐子; 真部 淳
Japanese Journal of Radiology, 42, Suppl., 5, 5, (公社)日本医学放射線学会, 2024年02月
日本語 - Hematopoietic cell transplantation for hematological malignancies in Bloom syndrome.
Yohei Nishiyama; Kazuyoshi Mizuki; Akihiro Hoshino; Shinsuke Hirabayashi; Tatsuya Magara; Miho Ashiarai; Satoshi Miyamoto; Rintaro Ono; Shuhei Takahashi; Yosuke Hosoya; Daiki Niizato; Hiroki Yoshihara; Akira Nishimura; Noriko Mitsuiki; Takahiro Kamiya; Kei Takasawa; Michiko Kajiwara; Hirokazu Kanegane; Tomohiro Morio; Atsushi Manabe; Takeshi Isoda; Daisuke Hasegawa; Masatoshi Takagi
Pediatric blood & cancer, e30655, 2023年08月29日, [国際誌]
英語 - Dominant-negative type of IKZF1 deletion showed a favorable prognosis in adult B-cell acute lymphoblastic leukemia.
Hiroyuki Kimura; Masahiro Onozawa; Shota Yoshida; Naoki Miyashita; Shota Yokoyama; Toshihiro Matsukawa; Shinsuke Hirabayashi; Hideki Goto; Tomoyuki Endo; Satoshi Oguri; Shinichi Fujisawa; Akio Mori; Takeshi Kondo; Daisuke Hidaka; Kohei Okada; Shuichi Ota; Yasutaka Kakinoki; Yutaka Tsutsumi; Satoshi Yamamoto; Takuto Miyagishima; Junichi Hashiguchi; Takahiro Nagashima; Makoto Ibata; Kentaro Wakasa; Yoshihito Haseyama; Katsuya Fujimoto; Toshimichi Ishihara; Hajime Sakai; Takanori Teshima
Annals of hematology, 2023年08月19日, [国際誌]
英語, 研究論文(学術雑誌), IKZF1 deletion is a recurrent genomic alteration in B-cell acute lymphoblastic leukemia (B-ALL) and is divided into dominant-negative (DN) and loss of function (LOF) deletions. The prognostic impact of each deletion has not been fully elucidated. We retrospectively analyzed 117 patients with adult B-ALL including 60 patients with BCR::ABL1-positive B-ALL and 57 patients with BCR::ABL1-negative B-ALL by the fluorescence in situ hybridization (FISH) method for IKZF1 deletion and multiplex PCR for the 4 most common IKZF1 deletions (∆4-7, ∆2-7, ∆2-8, and ∆4-8). Samples, in which IKZF1 deletion was detected by FISH but a specific type of deletion was not identified by the PCR, were categorized as "other." Patients were classified into a DN group that had at least 1 allele of ∆4-7 (n = 23), LOF and other group (n = 40), and wildtype group (n = 54). DN type IKZF1 deletions were found in 33.3% of BCR::ABL1-positive cases and 5.2% of BCR::ABL1-negative cases. LOF and other type IKZF1 deletions were found in 43.4% of BCR::ABL1-positive cases and 24.6% of BCR::ABL1-negative cases. Patients with the DN group showed significantly higher overall survival (OS) than that of the LOF and other and WT groups (P = 0.011). Multivariate analysis including age, WBC counts, complex karyotype, and DN type IKZF1 deletion showed that the DN type of IKZF1 deletion (HR = 0.22, P = 0.013) had a positive impact and age ≥ 65 (HR = 1.92, P = 0.029) had a negative impact on OS. The prognostic impact of IKZF1 deletion depends on the type of deletion and DN type of IKZF1 deletion showed better prognosis in adult B-ALL patients.Clinical trial registration This study was part of a prospective observational study (Hokkaido Leukemia Net, UMIN000048611). It was conducted in compliance with ethical principles based on the Helsinki Declaration and was approved by the institutional review board of Hokkaido University Hospital (#015-0344). - Prognostic impact of FLT3-ITD, NPM1 mutation and CEBPA bZIP domain mutation in cytogenetically normal acute myeloid leukemia: a Hokkaido Leukemia Net study.
Naoki Miyashita; Masahiro Onozawa; Shota Yoshida; Hiroyuki Kimura; Shogo Takahashi; Shota Yokoyama; Toshihiro Matsukawa; Shinsuke Hirabayashi; Shinichi Fujisawa; Akio Mori; Shuichi Ota; Yasutaka Kakinoki; Yutaka Tsutsumi; Satoshi Yamamoto; Takuto Miyagishima; Takahiro Nagashima; Makoto Ibata; Kentaro Wakasa; Yoshihito Haseyama; Katsuya Fujimoto; Toshimichi Ishihara; Hajime Sakai; Takeshi Kondo; Takanori Teshima
International journal of hematology, 118, 1, 36, 46, 2023年02月28日, [国内誌]
英語, 研究論文(学術雑誌), Mutation status of FLT3, NPM1, and CEBPA is used to classify the prognosis of acute myeloid leukemia, but its significance in patients with cytogenetically normal (CN) AML is unclear. We prospectively analyzed these genes in 295 patients with CN-AML and identified 76 (25.8%) FLT3-ITD, 113 (38.3%) NPM1 mutations, and 30 (10.2%) CEBPA biallelic mutations. We found that patients with FLT3-ITD had a poor prognosis at any age, while patients with CEBPA biallelic mutation were younger and had a better prognosis. FLT3-ITD and NPM1 mutations were correlated, and the favorable prognostic impact of being FLT3-ITD negative and NPM1 mutation positive was evident only in patients aged 65 years or more. For CEBPA, 86.7% of the patients with biallelic mutation and 9.1% of patients with the single allele mutation had in-frame mutations in the bZIP domain, which were strongly associated with a favorable prognosis. Multivariate analysis showed that age < 65 years, FLT3-ITD and CEBPA bZIP in-frame mutation were independent prognostic factors. The results suggest that analyzing these gene mutations at diagnosis can inform selection of the optimal intensity of therapy for patients with CN-AML. - The heterozygous NUDT15 variant is not associated with the severity of 6-mercaptopurine-related side effects in early intensification therapy for childhood acute lymphoblastic leukemia
Jimei Zhao; Masahiro Ueki; Saori Sawai; Minako Sugiyama; Yukayo Terashita; Shinsuke Hirabayashi; Yuko Cho; Ryoji Kobayashi; Yoichi Tanaka; Atsushi Manabe
EJC Paediatric Oncology, 1, 100006, 100006, Elsevier BV, 2023年
研究論文(学術雑誌) - Clinical characteristics and outcomes of B-cell precursor ALL with MEF2D rearrangements: a retrospective study by the Ponte di Legno Childhood ALL Working Group.
Kentaro Ohki; Ellie R Butler; Nobutaka Kiyokawa; Shinsuke Hirabayashi; Anke K Bergmann; Anja Möricke; Judith M Boer; Hélène Cavé; Giovanni Cazzaniga; Allen Eng Juh Yeoh; Masashi Sanada; Toshihiko Imamura; Hiroto Inaba; Charles G Mullighan; Mignon L Loh; Ulrika Norén-Nyström; Lee-Yung Shih; Marketa Zaliova; Ching-Hon Pui; Oskar A Haas; Christine J Harrison; Anthony V Moorman; Atsushi Manabe
Leukemia, 2022年10月29日, [国際誌]
英語, 研究論文(学術雑誌) - A retrospective analysis of azacitidine treatment for juvenile myelomonocytic leukemia.
Yuko Honda; Hideki Muramatsu; Yuka Nanjo; Shinsuke Hirabayashi; Toru Meguro; Nao Yoshida; Harumi Kakuda; Shuichi Ozono; Manabu Wakamatsu; Hiroshi Moritake; Masahiro Yasui; Hideki Sano; Atsushi Manabe; Kazuo Sakashita
International journal of hematology, 115, 2, 263, 268, 2022年02月, [国内誌]
英語, 研究論文(学術雑誌), Juvenile myelomonocytic leukemia (JMML) is a pediatric hematological malignancy with a poor prognosis. Although several case series have been published describing hematological and molecular responses to azacitidine (AZA) treatment in patients with JMML, the efficacy and safety profile of AZA is not well investigated, especially in Asian children and children undergoing hematopoietic stem cell transplantation (HSCT). We retrospectively analyzed 5 patients who received a total of 12 cycles (median 2 cycles) of AZA treatment in Japan. All five patients were boys and their ages at the time of treatment were 21, 23, 24, 26, and 46 months, respectively. All five patients tolerated AZA treatment, including four patients who received AZA after HSCT. Therapeutic toxicity with AZA was mostly limited to hematological toxicity. The only serious non-hematological adverse event was hyperbilirubinemia (grades III-IV) observed in a patient who received AZA after a second HSCT. Two out of five patients treated with AZA achieved a partial response (PR), while three patients treated for post-transplant relapse did not have an objective response. Future prospective studies should be conducted to develop combination therapies with AZA and other molecular targeted drugs for high-risk patients. - Notable therapeutic response in a patient with systemic juvenile xanthogranuloma with KIF5B-ALK fusion.
Minako Sugiyama; Shinsuke Hirabayashi; Yukitomo Ishi; Junko Kikuchi; Ayako Ishikura; Hiroaki Motegi; Yuki Ueda; Saori Sawai; Kazuya Hara; Yukayo Terashita; Yuko Cho; Emi Takakuwa; Shohei Honda; Shigeru Yamaguchi; Ichiro Kinoshita; Atsushi Manabe
Pediatric blood & cancer, 68, 11, e29227, 2021年11月, [国際誌]
英語 - Association of Unbalanced Translocation der(1;7) with Germline GATA2 Mutations.
Emilia J Kozyra; Gudrun Gohring; Dennis D Hickstein; Katherine R Calvo; Courtney D DiNardo; Michael Dworzak; Valerie de Haas; Jan Stary; Henrik Hasle; Akiko Shimamura; Mark D Fleming; Hiroto Inaba; Sara Lewis; Amy P Hsu; Steven M Holland; Danielle E Arnold; Cristina Mecucci; Sioban B Keel; Alison A Bertuch; Kiran Tawana; Shlomit Barzilai-Birenboim; Shinsuke Hirabayashi; Masahiro Onozawa; Shaohua Lei; Helena Alaiz; Hajnalka Andrikovics; David Betts; H Berna Beverloo; Jochen Buechner; Martin Čermák; Jose Cervera; Olga Haus; Kirsi Jahnukainen; Kalliopi Manola; Karin Nebral; Francesco Pasquali; Joelle Tchinda; Dominik Turkiewicz; Nadine Van Roy; Zuzana Zemanova; Victor B Pastor; Brigitte Strahm; Peter Nöllke; Charlotte M Niemeyer; Brigitte Schlegelberger; Ayami Yoshimi; Marcin W Wlodarski
Blood, 138, 23, 2441, 2445, 2021年09月01日, [国際誌]
英語, 研究論文(学術雑誌) - High-grade neuroepithelial tumor with BCL6 corepressor-alteration presenting pathological and radiological calcification: A case report.
Yukitomo Ishi; Ai Shimizu; Emi Takakuwa; Minako Sugiyama; Michinari Okamoto; Hiroaki Motegi; Shinsuke Hirabayashi; Yuko Cho; Akihiro Iguchi; Atsushi Manabe; Sumihito Nobusawa; Shinya Tanaka; Shigeru Yamaguchi
Pathology international, 71, 5, 348, 354, 2021年05月, [国際誌]
英語, A 5-year-old girl presented with headache and vomiting. Head computed tomography and magnetic resonance imaging showed a right frontal lobe tumor with marked calcification. The patient underwent resection surgery with suspicion of anaplastic ependymoma, and the tumor was gross totally removed. Pathological examination revealed areas of dense tumor cells with a high nucleocytoplasmic ratio and myxoid areas consisting of tumor cells with a round-shaped nucleus and eosinophilic cytoplasm. Perivascular pseudorosette, necrosis, circumscribed growth, and microcalcification were also observed. Immunohistochemistry demonstrated negative staining for glial fibrillary protein and epithelial membrane antigen. Diagnosis of a high-grade neuroepithelial tumor (HGNET) with BCL6 corepressor (BCOR) alteration was made based on pathological findings and internal tandem duplication in the exon 15 of BCOR. Although calcification on radiological and pathological examination is not typical, it would be essential to recognize that calcification could appear in HGNET-BCOR. - Clinical characteristics and outcomes of B-ALL with ZNF384 rearrangements: a retrospective analysis by the Ponte di Legno Childhood ALL Working Group.
Shinsuke Hirabayashi; Ellie R Butler; Kentaro Ohki; Nobutaka Kiyokawa; Anke K Bergmann; Anja Möricke; Judith M Boer; Hélène Cavé; Giovanni Cazzaniga; Allen Eng Juh Yeoh; Masashi Sanada; Toshihiko Imamura; Hiroto Inaba; Charles Mullighan; Mignon L Loh; Ulrika Norén-Nyström; Agata Pastorczak; Lee-Yung Shih; Marketa Zaliova; Ching-Hon Pui; Oskar A Haas; Christine J Harrison; Anthony V Moorman; Atsushi Manabe
Leukemia, 35, 11, 3272, 3277, 2021年03月10日, [国際誌]
英語, 研究論文(学術雑誌) - Ruxolitinib for hematopoietic cell transplantation-associated hemophagocytic lymphohistiocytosis.
Rintaro Ono; Miho Ashiarai; Shinsuke Hirabayashi; Kazuyoshi Mizuki; Yosuke Hosoya; Hiroki Yoshihara; Junya Ohtake; Shinichiro Mori; Atsushi Manabe; Daisuke Hasegawa
International journal of hematology, 113, 2, 297, 301, 2021年02月, [国内誌]
英語, 研究論文(学術雑誌), Hemophagocytic lymphohistiocytosis (HLH) is a severe complication after allogeneic hematopoietic cell transplantation (HCT) and can cause graft failure or multi-organ failure. Here, we report two children with refractory HCT-associated HLH treated with ruxolitinib. In the first patient, ruxolitinib resolved fever, cytopenia and hyperferritinemia. In another patient, although severe hepatic failure, which developed and worsened before the administration of ruxolitinib, was irreversible, rapid improvement in fever, leukopenia and hyperferritinemia was observed. Of note, multiplex cytokine profiling showed amelioration of cytokine storm in both patients. Ruxolitinib may be an encouraging option for HCT-associated HLH. - Vaginal Transmission of Cancer from Mothers with Cervical Cancer to Infants.
Ayumu Arakawa; Hitoshi Ichikawa; Takashi Kubo; Noriko Motoi; Tadashi Kumamoto; Miho Nakajima; Kan Yonemori; Emi Noguchi; Kuniko Sunami; Kouya Shiraishi; Hiroki Kakishima; Hiroshi Yoshida; Tomoro Hishiki; Naonori Kawakubo; Takafumi Kuroda; Takako Kiyokawa; Kyosuke Yamada; Nozomu Yanaihara; Kazuaki Takahashi; Aikou Okamoto; Shinsuke Hirabayashi; Daisuke Hasegawa; Atsushi Manabe; Kentaro Ono; Masaki Matsuoka; Yasuhito Arai; Yosuke Togashi; Tatsuhiro Shibata; Hiroyoshi Nishikawa; Kazunori Aoki; Noboru Yamamoto; Takashi Kohno; Chitose Ogawa
The New England journal of medicine, 384, 1, 42, 50, 2021年01月07日, [査読有り], [国際誌]
英語, 研究論文(学術雑誌), Two cases of pediatric lung cancer (in 23-month-old and 6-year-old boys) resulting from mother-to-infant transmission of uterine cervical tumors were incidentally detected during routine next-generation sequencing of paired samples of tumor and normal tissue. Spontaneous regression of some lesions in the first child and slow growth of the tumor mass in the second child suggested the existence of alloimmune responses against the transmitted tumors. Immune checkpoint inhibitor therapy with nivolumab led to a strong regression of all remaining tumors in the first child. (Funded by the Japan Agency for Medical Research and Development and others; TOP-GEAR UMIN Clinical Trials Registry number, UMIN000011141.). - DIAGNOSTIC CAPABILITY OF CSF-PLAP ON INTRACRANIAL GERM CELL TUMOR
Michinari Okamoto; Shigeru Yamaguchi; Yukitomo Ishi; Hiroaki Motegi; Yukayo Terashita; Shinsuke Hirabayashi; Minako Sugiyama; Yuko Cho; Akihiro Iguchi; Atushi Manabe; Kiyohiro Houkin
NEURO-ONCOLOGY, 22, 334, 334, 2020年12月, [査読有り]
英語 - Acquisition of monosomy 7 and a RUNX1 mutation in Pearson syndrome
Akira Nishimura; Shinsuke Hirabayashi; Daisuke Hasegawa; Kenichi Yoshida; Yuichi Shiraishi; Miho Ashiarai; Yosuke Hosoya; Tohru Fujiwara; Hideo Harigae; Satoru Miyano; Seishi Ogawa; Atsushi Manabe
Pediatric Blood & Cancer, Wiley, 2020年11月16日
研究論文(学術雑誌) - Diagnostic Capability of Cerebrospinal Fluid-Placental Alkaline Phosphatase Value in Intracranial Germ Cell Tumor.
Michinari Okamoto; Shigeru Yamaguchi; Yukitomo Ishi; Hiroaki Motegi; Takashi Mori; Takayuki Hashimoto; Yukayo Terashita; Shinsuke Hirabayashi; Minako Sugiyama; Akihiro Iguchi; Yuko Cho; Atsushi Manabe; Kiyohiro Houkin
Oncology, 99, 1, 1, 9, 2020年09月09日, [査読有り], [国際誌]
英語, 研究論文(学術雑誌), OBJECTIVE: Most types of intracranial germ cell tumors (IGCTs) are sensitive to chemoradiation. However, biopsy specimens are usually small and thus cannot be used for obtaining an accurate pathological diagnosis. Recently, the cerebrospinal fluid (CSF) placental alkaline phosphatase (PLAP) value has been considered a new biomarker of IGCTs. The present study aimed to evaluate the discriminatory characteristics of the CSF-PLAP value upon diagnosis and at the time of recurrence in patients with IGCTs. METHODS: Between 2015 and 2019, this study included 37 patients with tumors located in the intraventricular and/or periventricular region. The CSF-PLAP level was assessed before the patients received any treatment. The PLAP level was evaluated during and after first-line chemoradiotherapy in 7 patients with IGCTs. The CSF-PLAP values were compared according to histological diagnosis, and the correlation between these values and radiographical features was assessed. The CSF-PLAP values of 6 patients with IGCTs with suspected recurrence were evaluated based on neuroimaging findings. RESULTS: The CSF-PLAP values were significantly higher in patients with IGCTs than in those with other types of brain tumor (n = 19 vs. 18; median: 359.0 vs. <8.0 pg/mL). The specificity and sensitivity were 88 and 95%, respectively, with a cutoff value of 8.0 pg/mL. In patients with IGCT, the CSF-PLAP value was higher in patients with germinoma than in those with nongerminomatous germ cell tumors (n = 12 vs. 7; median: 415.0 vs. 359.0 pg/mL). Regarding the time course, the CSF-PLAP value decreased to below the detection limit after the reception of first-line chemoradiotherapy in all 7 patients. A significant correlation was observed between the initial CSF-PLAP value and the tumor reduction volume after receiving first-line chemoradiotherapy (p < 0.0003, R2 = 0.6165, logY = 1.202logX - 1.727). Among the patients with suspected IGCT recurrence (n = 6), the CSF-PLAP value was high in patients with recurrence (n = 3; median: 259.0 pg/mL), and that in patients (n = 3) without recurrence was below the lower detection limit. CONCLUSIONS: The CSF-PLAP level is a useful biomarker during the initial diagnosis of IGCTs and at the time of recurrence. It may be associated with the volume of germinomatous components of tumors. - 小児血液・腫瘍性疾患の治療中にPRESによる非けいれん性てんかん重積を認めた2例
山本 薫; 代田 惇朗; 長谷川 大輔; 木村 俊介; 吉本 優里; 平林 真介; 細谷 要介; 野崎 太希; 横山 美奈; 真部 淳; 荻原 正明
日本小児科学会雑誌, 124, 9, 1391, 1396, (公社)日本小児科学会, 2020年09月
日本語, 症例1(4歳女児)。急性リンパ性白血病に対する寛解導入療法開始31日に意識障害、右下肢間代発作を認めた。その後も意識障害が持続し、3日後の脳波検査およびMRI検査にて可逆性後部白質脳症(PRES)による非けいれん性てんかん重積状態(NCSE)と診断された。クロバザム(CLB)を投与するもNCSEのコントロールに苦慮し、白血病の治療後も焦点てんかんが後遺症として残った。現在、CLBのの内服を継続し、てんかん発作は消失している。症例2(7歳女児)。全身転移を有する治療抵抗性横紋筋肉腫へのパゾパニブの投与中に左上肢の間代発作が出現し、頭部MRI検査にてPRESと診断された。その後は意識障害が遷延し、脳波検査でNCSEと判明、抗てんかん薬を投与したところ、NCSEは消失し、意識状態の改善が得られた。 - Clinical utility of target capture-based panel sequencing in hematological malignancies: A multicenter feasibility study.
Takahiko Yasuda; Masashi Sanada; Dai Nishijima; Takashi Kanamori; Yuka Iijima; Hiroyoshi Hattori; Akiko Saito; Hiroaki Miyoshi; Yuichi Ishikawa; Norio Asou; Kensuke Usuki; Shinsuke Hirabayashi; Motohiro Kato; Masaki Ri; Hiroshi Handa; Tadao Ishida; Hirohiko Shibayama; Masahiro Abe; Chisako Iriyama; Kennosuke Karube; Momoko Nishikori; Koichi Ohshima; Keisuke Kataoka; Kenichi Yoshida; Yuichi Shiraishi; Hiroaki Goto; Souichi Adachi; Ryoji Kobayashi; Hitoshi Kiyoi; Yasushi Miyazaki; Seishi Ogawa; Hiroki Kurahashi; Hisayuki Yokoyama; Atsushi Manabe; Shinsuke Iida; Akihiro Tomita; Keizo Horibe
Cancer science, 111, 9, 3367, 3378, 2020年09月, [査読有り], [国際誌]
英語, 研究論文(学術雑誌), Although next-generation sequencing-based panel testing is well practiced in the field of cancer medicine for the identification of target molecules in solid tumors, the clinical utility and clinical issues surrounding panel testing in hematological malignancies have yet to be fully evaluated. We conducted a multicenter prospective clinical sequencing study to verify the feasibility of a panel test for hematological tumors, including acute myeloid leukemia, acute lymphoblastic leukemia, multiple myeloma, and diffuse large B-cell lymphoma. Out of 96 eligible patients, 79 patients (82%) showed potentially actionable findings, based on the clinical sequencing assays. We identified that genetic alterations with a strong clinical significance were found at a higher frequency in terms of diagnosis (n = 60; 63%) and prognosis (n = 61; 64%) than in terms of therapy (n = 8; 8%). Three patients who harbored a germline mutation in either DDX41 (n = 2) or BRCA2 (n = 1) were provided with genetic counseling. At 6 mo after sequencing, clinical actions based on the diagnostic (n = 5) or prognostic (n = 3) findings were reported, but no patients were enrolled in a clinical trial or received targeted therapies based on the sequencing results. These results suggest that panel testing for hematological malignancies would be feasible given the availability of useful diagnostic and prognostic information. This study is registered with the UMIN Clinical Trial Registry (UMIN000029879, multiple myeloma; UMIN000031343, adult acute myeloid leukemia; UMIN000033144, diffuse large B-cell lymphoma; and UMIN000034243, childhood leukemia). - Refractory malignant hepatocellular tumor consisting of hepatocellular carcinoma and hepatoblastoma in a 10-year-old male
Minako Sugiyama; Shinsuke Hirabayashi; Yukayo Terashita; Yuko Cho; Akihiro Iguchi; Yoshihito Ohhara; Daisuke Abo; Shohei Honda; Emi Takakuwa; Atsushi Manabe
Authorea, Inc., 2020年06月22日 - Synonymous GATA2 mutations result in selective loss of mutated RNA and are common in patients with GATA2 deficiency.
Emilia J Kozyra; Victor B Pastor; Stylianos Lefkopoulos; Sushree S Sahoo; Hauke Busch; Rebecca K Voss; Miriam Erlacher; Dirk Lebrecht; Enikoe A Szvetnik; Shinsuke Hirabayashi; Ramunė Pasaulienė; Lucia Pedace; Marco Tartaglia; Christian Klemann; Patrick Metzger; Melanie Boerries; Albert Catala; Henrik Hasle; Valerie de Haas; Krisztián Kállay; Riccardo Masetti; Barbara De Moerloose; Michael Dworzak; Markus Schmugge; Owen Smith; Jan Starý; Ester Mejstrikova; Marek Ussowicz; Emma Morris; Preeti Singh; Matthew Collin; Marta Derecka; Gudrun Göhring; Christian Flotho; Brigitte Strahm; Franco Locatelli; Charlotte M Niemeyer; Eirini Trompouki; Marcin W Wlodarski
Leukemia, 2020年06月18日, [査読有り], [国際誌]
英語, 研究論文(学術雑誌), Deficiency of the transcription factor GATA2 is a highly penetrant genetic disorder predisposing to myelodysplastic syndromes (MDS) and immunodeficiency. It has been recognized as the most common cause underlying primary MDS in children. Triggered by the discovery of a recurrent synonymous GATA2 variant, we systematically investigated 911 patients with phenotype of pediatric MDS or cellular deficiencies for the presence of synonymous alterations in GATA2. In total, we identified nine individuals with five heterozygous synonymous mutations: c.351C>G, p.T117T (N = 4); c.649C>T, p.L217L; c.981G>A, p.G327G; c.1023C>T, p.A341A; and c.1416G>A, p.P472P (N = 2). They accounted for 8.2% (9/110) of cases with GATA2 deficiency in our cohort and resulted in selective loss of mutant RNA. While for the hotspot mutation (c.351C>G) a splicing error leading to RNA and protein reduction was identified, severe, likely late stage RNA loss without splicing disruption was found for other mutations. Finally, the synonymous mutations did not alter protein function or stability. In summary, synonymous GATA2 substitutions are a new common cause of GATA2 deficiency. These findings have broad implications for genetic counseling and pathogenic variant discovery in Mendelian disorders. - Very late relapse cases of TCF3-ZNF384-positive acute lymphoblastic leukemia.
Akira Nishimura; Daisuke Hasegawa; Shinsuke Hirabayashi; Shoichiro Kanabuchi; Kaoru Yamamoto; Saori Aiga; Misa Nishitani; Yosuke Hosoya; Yasushi Noguchi; Kentaro Ohki; Nobutaka Kiyokawa; Shinichiro Mori; Atsushi Manabe
Pediatric blood & cancer, 66, 11, e27891, 2019年11月, [査読有り], [国際誌]
英語 - Germline GATA2変異を伴う骨髄異形成症候群(MDS)の1例
水城 和義; 平林 真介; 長谷川 大輔; 山本 俊亮; 山本 薫; 足洗 美穂; 小野 林太郎; 細谷 要介; 鈴木 美慧; 松本 公宏; 川口 裕之; 真部 淳
臨床血液, 60, 10, 1502, 1502, (一社)日本血液学会-東京事務局, 2019年10月
日本語 - 長期にわたる免疫抑制治療後にステロイド離脱が可能となった移植後自己免疫性溶血性貧血(AIHA)
小野 林太郎; 細谷 要介; 山本 俊亮; 山本 薫; 西村 聡; 足洗 美穂; 平林 真介; 長谷川 大輔; 真部 淳
日本小児血液・がん学会雑誌, 56, 4, 324, 324, (一社)日本小児血液・がん学会, 2019年10月
日本語 - Dasatinib and low-intensity chemotherapy for Philadelphia chromosome-positive acute lymphoblastic leukemia in a child with Down syndrome.
Shinsuke Hirabayashi; Daisuke Hasegawa; Kaoru Yamamoto; Akira Nishimura; Yosuke Hosoya; Takuya Shuo; Nobutaka Kiyokawa; Masatomo Miura; Naoto Takahashi; Atsushi Manabe
Pediatric blood & cancer, 66, 5, e27612, 2019年05月, [査読有り], [国際誌]
英語 - Duplication of ALK F1245 missense mutation due to acquired uniparental disomy associated with aggressive progression in a patient with relapsed neuroblastoma.
Shunsuke Kimura; Daisuke Hasegawa; Yuri Yoshimoto; Masafumi Seki; Atsuro Daida; Masahiro Sekiguchi; Shinsuke Hirabayashi; Yosuke Hosoya; Masao Kobayashi; Satoru Miyano; Seishi Ogawa; Junko Takita; Atsushi Manabe
Oncology letters, 17, 3, 3323, 3329, 2019年03月, [査読有り], [国際誌]
英語, 研究論文(学術雑誌), Recent genome-wide analysis of neuroblastoma (NBL) revealed amplification and heterozygous mutation of anaplastic lymphoma kinase (ALK) are responsible for oncogenicity, frequently observed during relapses. A 3-year-old girl with relapsed high-risk NBL had a heterozygous ALK F1245L mutation at diagnosis, which became homozygous due to uniparental disomy (UPD) of the entire chromosome 2, confirmed by single nucleotide polymorphism array and variant allele frequency of this mutation. The ALK inhibitor, crizotinib, failed to control the tumor and the patient died of the disease. Further genomic analysis using targeted capture sequencing for 381 genes related to pediatric cancers identified more alterations acquired at relapse, such as TSC complex subunit 2 and protein tyrosine phosphatase receptor type D. In addition to these several acquired mutations, this extremely rare duplication of ALK mutation might explain the aggressive clinical course after relapse, because acquired UPD, resulting in the duplication of an oncogenic mutation, has been reported for various neoplasms. Although a clinical benefit of ALK inhibitors in patients with NBL has not been confirmed yet, a treatment based on the ALK mutation status will be promising in future using more potent next-generation ALK inhibitors. - 寛解導入療法中に肺胞出血をきたしNO吸入療法が有効であったAMLの1例
足洗 美穂; 梅原 直; 黒子 由梨香; 山本 薫; 山本 俊亮; 小野 林太郎; 平林 真介; 細谷 要介; 長谷川 大輔; 真部 淳
日本小児科学会雑誌, 123, 2, 320, 320, (公社)日本小児科学会, 2019年02月
日本語 - Diamond-Blackfan貧血に対する強度減弱前処置を用いた骨髄移植
西村 聡; 平林 真介; 山本 俊亮; 相賀 咲央莉; 西谷 美佐; 細谷 要介; 森 慎一郎; 長谷川 大輔; 真部 淳
日本小児血液・がん学会雑誌, 55, 5, 432, 435, (一社)日本小児血液・がん学会, 2019年01月
日本語 - Clinical and molecular characteristics of MEF2D fusion-positive B-cell precursor acute lymphoblastic leukemia in childhood, including a novel translocation resulting in MEF2D-HNRNPH1 gene fusion.
Kentaro Ohki; Nobutaka Kiyokawa; Yuya Saito; Shinsuke Hirabayashi; Kazuhiko Nakabayashi; Hitoshi Ichikawa; Yukihide Momozawa; Kohji Okamura; Ai Yoshimi; Hiroko Ogata-Kawata; Hiromi Sakamoto; Motohiro Kato; Keitaro Fukushima; Daisuke Hasegawa; Hiroko Fukushima; Masako Imai; Ryosuke Kajiwara; Takashi Koike; Isao Komori; Atsushi Matsui; Makiko Mori; Koichi Moriwaki; Yasushi Noguchi; Myoung-Ja Park; Takahiro Ueda; Shohei Yamamoto; Koichi Matsuda; Teruhiko Yoshida; Kenji Matsumoto; Kenichiro Hata; Michiaki Kubo; Yoichi Matsubara; Hiroyuki Takahashi; Takashi Fukushima; Yasuhide Hayashi; Katsuyoshi Koh; Atsushi Manabe; Akira Ohara
Haematologica, 104, 1, 128, 137, 2019年01月, [査読有り], [国際誌]
英語, 研究論文(学術雑誌), Fusion genes involving MEF2D have recently been identified in precursor B-cell acute lymphoblastic leukemia, mutually exclusive of the common risk stratifying genetic abnormalities, although their true incidence and associated clinical characteristics remain unknown. We identified 16 cases of acute lymphoblastic leukemia and 1 of lymphoma harboring MEF2D fusions, including MEF2D-BCL9 (n=10), MEF2D-HNRNPUL1 (n=6), and one novel MEF2D-HNRNPH1 fusion. The incidence of MEF2D fusions overall was 2.4% among consecutive precursor B-cell acute lymphoblastic leukemia patients enrolled onto a single clinical trial. They frequently showed a cytoplasmic μ chain-positive pre-B immunophenotype, and often expressed an aberrant CD5 antigen. Besides up- and down-regulation of HDAC9 and MEF2C, elevated GATA3 expression was also a characteristic feature of MEF2D fusion-positive patients. Mutations of PHF6, recurrent in T-cell acute lymphoblastic leukemia, also showed an unexpectedly high frequency (50%) in these patients. MEF2D fusion-positive patients were older (median age 9 years) with elevated WBC counts (median: 27,300/ml) at presentation and, as a result, were mostly classified as NCI high risk. Although they responded well to steroid treatment, MEF2D fusion-positive patients showed a significantly worse outcome, with 53.3% relapse and subsequent death. Stem cell transplantation was ineffective as salvage therapy. Interestingly, relapse was frequently associated with the presence of CDKN2A/CDKN2B gene deletions. Our observations indicate that MEF2D fusions comprise a distinct subgroup of precursor B-cell acute lymphoblastic leukemia with a characteristic immunophenotype and gene expression signature, associated with distinct clinical features. - -7が生じたPearson症候群に対する移植経験
西村 聡; 平林 真介; 山本 俊亮; 山本 一希; 山本 薫; 相賀 咲央莉; 代田 惇朗; 足洗 美穂; 細谷 要介; 藤原 亨; 張替 秀郎; 森 愼一郎; 長谷川 大輔; 真部 淳
日本小児血液・がん学会雑誌, 55, 3, 334, 335, (一社)日本小児血液・がん学会, 2018年10月
日本語 - 腸管気腫を来した血液腫瘍性疾患の2例
山本 俊亮; 西村 聡; 小野 林太郎; 山本 薫; 足洗 美穂; 平林 真介; 細谷 要介; 長谷川 大輔; 真部 淳
日本小児血液・がん学会雑誌, 55, 4, 335, 335, (一社)日本小児血液・がん学会, 2018年10月
日本語 - 診断後10年で再発をきたしたTCF3-ZNF384陽性急性リンパ性白血病の1例(TCF3-ZNF384 positive acute lymphoblastic leukemia recurring 10 years after diagnosis)
西村 聡; 平林 真介; 金淵 昭一郎; 山本 薫; 相賀 咲央莉; 細谷 要介; 大木 健太郎; 清河 信敬; 長谷川 大輔; 真部 淳
臨床血液, 59, 9, 1649, 1649, (一社)日本血液学会-東京事務局, 2018年09月
英語 - 急激な臨床経過を辿ったT細胞/骨髄性混合形質型急性白血病/リンパ腫(T/Myeloid mixed phenotype leukemia/lymphoma presenting aggressive clinical course)
長谷川 大輔; 平林 真介; 宮本 智史; 木村 俊介; 吉本 優里; 細谷 要介; 吉田 健一; 小川 誠司; 真部 淳
臨床血液, 59, 9, 1650, 1650, (一社)日本血液学会-東京事務局, 2018年09月
英語 - 急性前骨髄球性白血病に生じた髄注後の亜急性白質脳症の一例(Subacute leukoencephalopathy after intrathecal methotrexate in a patient with APL)
平林 真介; 西村 聡; 山本 薫; 山本 俊亮; 細谷 要介; 野崎 太希; 長谷川 大輔; 真部 淳
臨床血液, 59, 9, 1771, 1771, (一社)日本血液学会-東京事務局, 2018年09月
英語 - MDS-predisposing syndromes MDS関連AMLを来たしたBloom症候群の1例
平林 真介; 長谷川 大輔; 山本 一希; 相賀 咲央莉; 西村 聡; 木村 俊介; 細谷 要介; 奥野 友介; 村松 秀城; 小島 勢二; 真部 淳
日本小児血液・がん学会雑誌, 55, 1, 68, 68, (一社)日本小児血液・がん学会, 2018年06月
日本語 - Constitutional abnormalities of IDH1 combined with secondary mutations predispose a patient with Maffucci syndrome to acute lymphoblastic leukemia.
Shinsuke Hirabayashi; Masafumi Seki; Daisuke Hasegawa; Motohiro Kato; Nobuyuki Hyakuna; Takuya Shuo; Shunsuke Kimura; Kenichi Yoshida; Keisuke Kataoka; Yoichi Fujii; Yuichi Shiraishi; Kenichi Chiba; Hiroko Tanaka; Nobutaka Kiyokawa; Satoru Miyano; Seishi Ogawa; Junko Takita; Atsushi Manabe
Pediatric blood & cancer, 64, 12, 2017年12月, [査読有り], [国際誌]
英語, 研究論文(学術雑誌), Maffucci syndrome is a nonhereditary disorder caused by somatic mosaic isocitrate dehydrogenase 1 or 2 (IDH1 or IDH2) mutations and is characterized by multiple enchondromas along with hemangiomas. Malignant transformation of enchondromas to chondrosarcomas and secondary neoplasms, such as brain tumors or acute myeloid leukemia, are serious complications. A 15-year-old female with Maffucci syndrome developed B-cell precursor acute lymphoblastic leukemia (BCP-ALL). A somatic mutation in IDH1 was detected in hemangioma and leukemic cells. KRAS mutation and deletion of IKZF1 were detected in leukemic cells. Patients with Maffucci syndrome may, therefore, be at risk of BCP-ALL associated with secondary genetic events that affect lymphocyte differentiation. - Bortezomib combined with standard induction chemotherapy in Japanese children with refractory acute lymphoblastic leukemia.
Akihiro Iguchi; Yuko Cho; Minako Sugiyama; Yukayo Terashita; Tadashi Ariga; Yosuke Hosoya; Shinsuke Hirabayashi; Atsushi Manabe; Keisuke Hara; Tetsuya Aiba; Tsugumi Shiokawa; Hiroko Tada; Norihiro Sato
International journal of hematology, 106, 2, 291, 298, 2017年08月, [査読有り], [国内誌]
英語, 研究論文(学術雑誌), Bortezomib has been shown to be effective and well-tolerated in patients with refractory acute lymphoblastic leukemia (ALL) in the Therapeutic Advances in Childhood Leukemia trial. However, the safety and efficacy of bortezomib have not been evaluated in Japanese pediatric patients. Here, we report the results of a clinical trial designed to evaluate the safety of bortezomib combined with induction chemotherapy in Japanese children with refractory ALL. A total of six patients with B-precursor ALL were enrolled in this study. Four-dose bortezomib (1.3 mg/m2/dose) combined with two standard induction chemotherapies was used. Prolonged pancytopenia (grade 4) was observed in all patients. Four of the six patients developed severe infectious complications. Peripheral neuropathy (grade 2) occurred in five patients. The individual plasma bortezomib concentration-time profiles were not related to toxicity and efficacy. Five patients were evaluable for response, and four patients achieved complete response (CR) or CR without platelet recovery (80%). In conclusion, four-dose bortezomib (1.3 mg/m2/dose) combined with standard re-induction chemotherapy was associated with a high risk of infectious complications induced by prolonged neutropenia, although high efficacy has been achieved for Japanese pediatric patients with refractory ALL. Attention must be given to severe infectious complications when performing re-induction chemotherapy including bortezomib. - Heterogeneity of GATA2-related myeloid neoplasms.
Shinsuke Hirabayashi; Marcin W Wlodarski; Emilia Kozyra; Charlotte M Niemeyer
International journal of hematology, 106, 2, 175, 182, 2017年08月, [査読有り], [国内誌]
英語, 研究論文(学術雑誌), The GATA2 gene codes for a master hematopoietic transcription factor that is essential for the proliferation and maintenance of hematopoietic stem and progenitor cells. Heterozygous germline mutations in GATA2 have been initially associated with several clinical entities that are now collectively defined as GATA2 deficiency. Despite pleiotropic clinical manifestations, the high propensity for the development of myelodysplastic syndromes (MDS) constitutes the most common clinical denominator of this major MDS predisposition syndrome. The immunological phenotypes can be variable and mostly include deficiency of monocytes and/or B cells. Thus far, nearly 380 GATA2-deficient patients had been reported, with a roughly estimated prevalence of myeloid neoplasia of at least 75%. The most common abnormal karyotypes associated with GATA2-related MDS are monosomy 7, der(1;7) and trisomy 8. The overall clinical penetrance seems to be nearly complete for this transcriptopathy disorder. The high-risk MDS subtypes and karyotypes, and the underlying immunodeficiency guide decision-making toward timely stem cell transplantation. - C型肝炎ウイルス持続感染を伴う再発急性骨髄性白血病の小児に対する化学療法の経験
木村 俊介; 平林 真介; 長谷川 大輔; 角谷 和歌子; 瀬谷 恵; 松井 俊大; 吉本 優里; 細谷 要介; 森 信好; 松井 陽; 真部 淳
臨床血液, 58, 6, 619, 623, (一社)日本血液学会-東京事務局, 2017年06月
日本語 - ZNF384関連融合遺伝子はALLの細胞マーカーに特徴を有する亜群を規定する
清河 信敬; 大木 健太郎; 平林 真介; 福島 敬; 康 勝好; 真部 淳; 小原 明
Cytometry Research, 27, Suppl., 64, 64, (一社)日本サイトメトリー学会, 2017年06月
日本語 - ZNF384-related fusion genes define a subgroup of childhood B-cell precursor acute lymphoblastic leukemia with a characteristic immunotype.
Shinsuke Hirabayashi; Kentaro Ohki; Kazuhiko Nakabayashi; Hitoshi Ichikawa; Yukihide Momozawa; Kohji Okamura; Akinori Yaguchi; Kazuki Terada; Yuya Saito; Ai Yoshimi; Hiroko Ogata-Kawata; Hiromi Sakamoto; Motohiro Kato; Junya Fujimura; Moeko Hino; Akitoshi Kinoshita; Harumi Kakuda; Hidemitsu Kurosawa; Keisuke Kato; Ryosuke Kajiwara; Koichi Moriwaki; Tsuyoshi Morimoto; Kozue Nakamura; Yasushi Noguchi; Tomoo Osumi; Kazuo Sakashita; Junko Takita; Yuki Yuza; Koich Matsuda; Teruhiko Yoshida; Kenji Matsumoto; Kenichiro Hata; Michiaki Kubo; Yoichi Matsubara; Takashi Fukushima; Katsuyoshi Koh; Atsushi Manabe; Akira Ohara; Nobutaka Kiyokawa
Haematologica, 102, 1, 118, 129, 2017年01月, [査読有り], [国際誌]
英語, 研究論文(学術雑誌), Fusion genes involving ZNF384 have recently been identified in B-cell precursor acute lymphoblastic leukemia, and 7 fusion partners have been reported. We further characterized this type of fusion gene by whole transcriptome sequencing and/or polymerase chain reaction. In addition to previously reported genes, we identified BMP2K as a novel fusion partner for ZNF384 Including the EP300-ZNF384 that we reported recently, the total frequency of ZNF384-related fusion genes was 4.1% in 291 B-cell precursor acute lymphoblastic leukemia patients enrolled in a single clinical trial, and TCF3-ZNF384 was the most recurrent, with a frequency of 2.4%. The characteristic immunophenotype of weak CD10 and aberrant CD13 and/or CD33 expression was revealed to be a common feature of the leukemic cells harboring ZNF384-related fusion genes. The signature gene expression profile in TCF3-ZNF384-positive patients was enriched in hematopoietic stem cell features and related to that of EP300-ZNF384-positive patients, but was significantly distinct from that of TCF3-PBX1-positive and ZNF384-fusion-negative patients. However, clinical features of TCF3-ZNF384-positive patients are markedly different from those of EP300-ZNF384-positive patients, exhibiting higher cell counts and a younger age at presentation. TCF3-ZNF384-positive patients revealed a significantly poorer steroid response and a higher frequency of relapse, and the additional activating mutations in RAS signaling pathway genes were detected by whole exome analysis in some of the cases. Our observations indicate that ZNF384-related fusion genes consist of a distinct subgroup of B-cell precursor acute lymphoblastic leukemia with a characteristic immunophenotype, while the clinical features depend on the functional properties of individual fusion partners. - Clinical and Molecular Heterogeneity of RTEL1 Deficiency.
Carsten Speckmann; Sushree Sangita Sahoo; Marta Rizzi; Shinsuke Hirabayashi; Axel Karow; Nina Kathrin Serwas; Marc Hoemberg; Natalja Damatova; Detlev Schindler; Jean-Baptiste Vannier; Simon J Boulton; Ulrich Pannicke; Gudrun Göhring; Kathrin Thomay; J J Verdu-Amoros; Holger Hauch; Wilhelm Woessmann; Gabriele Escherich; Eckart Laack; Liliana Rindle; Maximilian Seidl; Anne Rensing-Ehl; Ekkehart Lausch; Christine Jandrasits; Brigitte Strahm; Klaus Schwarz; Stephan R Ehl; Charlotte Niemeyer; Kaan Boztug; Marcin W Wlodarski
Frontiers in immunology, 8, 449, 449, 2017年, [査読有り], [国際誌]
英語, 研究論文(学術雑誌), Typical features of dyskeratosis congenita (DC) resulting from excessive telomere shortening include bone marrow failure (BMF), mucosal fragility, and pulmonary or liver fibrosis. In more severe cases, immune deficiency and recurring infections can add to disease severity. RTEL1 deficiency has recently been described as a major genetic etiology, but the molecular basis and clinical consequences of RTEL1-associated DC are incompletely characterized. We report our observations in a cohort of six patients: five with novel biallelic RTEL1 mutations p.Trp456Cys, p.Ile425Thr, p.Cys1244ProfsX17, p.Pro884_Gln885ins53X13, and one with novel heterozygous mutation p.Val796AlafsX4. The most unifying features were hypocellular BMF in 6/6 and B-/NK-cell lymphopenia in 5/6 patients. In addition, three patients with homozygous mutations p.Trp456Cys or p.Ile425Thr also suffered from immunodeficiency, cerebellar hypoplasia, and enteropathy, consistent with Hoyeraal-Hreidarsson syndrome. Chromosomal breakage resembling a homologous recombination defect was detected in patient-derived fibroblasts but not in hematopoietic compartment. Notably, in both cellular compartments, differential expression of 1243aa and 1219/1300aa RTEL1 isoforms was observed. In fibroblasts, response to ionizing irradiation and non-homologous end joining were not impaired. Telomeric circles did not accumulate in patient-derived primary cells and lymphoblastoid cell lines, implying alternative pathomechanisms for telomeric loss. Overall, RTEL1-deficient cells exhibited a phenotype of replicative exhaustion, spontaneous apoptosis and senescence. Specifically, CD34+ cells failed to expand in vitro, B-cell development was compromised, and T-cells did not proliferate in long-term culture. Finally, we report on the natural history and outcome of our patients. While two patients died from infections, hematopoietic stem cell transplantation (HSCT) resulted in sustained engraftment in two patients. Whether chemotherapy negatively impacts on the course and onset of other DC-related symptoms remains open at present. Early-onset lung disease occurred in one of our patients after HSCT. In conclusion, RTEL deficiency can show a heterogeneous clinical picture ranging from mild hypocellular BMF with B/NK cell lymphopenia to early-onset, very severe, and rapidly progressing cellular deficiency. - Chemotherapy for a child with relapsed acute myeloid leukemia complicated with persistent hepatitis C virus infection.
Shunsuke Kimura; Shinsuke Hirabayashi; Daisuke Hasegawa; Wakako Sumiya; Megumi Seya; Toshihiro Matsui; Yuri Yoshimoto; Yosuke Hosoya; Nobuyoshi Mori; Akira Matsui; Atsushi Manabe
[Rinsho ketsueki] The Japanese journal of clinical hematology, 58, 6, 619, 623, 2017年, [査読有り], [国内誌]
日本語, 研究論文(学術雑誌), An 8-year-old Mongolian female was diagnosed with acute myeloid leukemia (AML) and treated at a hospital in Mongolia according to the BFM-AML2004 SR protocol. Although complete remission (CR) was achieved, chemotherapy was interrupted because of shortage of drugs. The patient moved to Japan 7 months after diagnosis. Screening for viral infection revealed the presence of hepatitis C virus (HCV) antibody and RNA. At 11 months after initial diagnosis, the patient experienced bone marrow relapse and a RUNX1-RUNX1T1 fusion transcript was detected. Considering the inadequate intensity of initial treatment and the persistent HCV infection, chemotherapy was preferred and initiated over hematopoietic cell transplantation. After the first course of induction therapy, a second CR was confirmed and the chimeric transcript disappeared. The viral load mildly increased during myelosuppression and transient elevation of liver enzymes was observed along with hematological recovery. HCV infection remained stable, without progression to reactivation of hepatitis C. Given the high risk of second relapse and liver fibrosis and sclerosis following chronic HCV infection, treatment against HCV may be indicated during second remission. - Familial hematological malignancies.
Shinsuke Hirabayashi; Atsushi Manabe
[Rinsho ketsueki] The Japanese journal of clinical hematology, 58, 10, 1878, 1883, 2017年, [査読有り], [国内誌]
日本語, 研究論文(学術雑誌), The World Health Organization (WHO) classification of tumors of the hematopoietic and lymphoid tissues was last updated in 2008. The study of cancer genomes has identified inherited genetic drivers that predispose cancer cells to clonal evolution. The revisions in the categories of myeloid neoplasms and acute leukemia were published as a monograph in 2016. We described familial hematological malignancies using the 2016 edition of the WHO classification. - Corrigendum: Clinical and Molecular Heterogeneity of RTEL1 Deficiency.
Carsten Speckmann; Sushree Sangita Sahoo; Marta Rizzi; Shinsuke Hirabayashi; Axel Karow; Nina Kathrin Serwas; Marc Hoemberg; Natalja Damatova; Detlev Schindler; Jean-Baptiste Vannier; Simon J Boulton; Ulrich Pannicke; Gudrun Göhring; Kathrin Thomay; J J Verdu-Amoros; Holger Hauch; Wilhelm Woessmann; Gabriele Escherich; Eckart Laack; Liliana Rindle; Maximilian Seidl; Anne Rensing-Ehl; Ekkehart Lausch; Christine Jandrasits; Brigitte Strahm; Klaus Schwarz; Stephan R Ehl; Charlotte Niemeyer; Kaan Boztug; Marcin W Wlodarski
Frontiers in immunology, 8, 1250, 1250, 2017年, [査読有り], [国際誌]
英語, 研究論文(学術雑誌), [This corrects the article on p. 449 in vol. 8, PMID: 28507545.]. - 劇症型G群溶血性連鎖球菌感染症に罹患した治療不応フィラデルフィア染色体陽性急性リンパ性白血病の一小児例(Invasive group G streptococcal infection in a child with refractory Philadelphia chromosome-positive acute lymphoblastic leukemia)
松井 俊大; 長谷川 大輔; 吉本 優里; 梅原 直; 平林 真介; 細谷 要介; 稲井 郁子; 熊本 忠史; 真部 淳
日本小児血液・がん学会雑誌, 53, 4, 338, 338, (一社)日本小児血液・がん学会, 2016年11月
英語 - 小児血液・がん疾患に対する治療中に可逆性後頭部白質脳症症候群(PRES)をきたした3例(Posterior reversible encephalopathy syndrome(PRES) in pediatric cancer patients)
代田 惇朗; 長谷川 大輔; 山本 一希; 瀬谷 恵; 木村 俊介; 吉本 優里; 平林 真介; 細谷 要介; 野崎 大希; 横山 美奈; 荻原 正明; 真部 淳
日本小児血液・がん学会雑誌, 53, 4, 368, 368, (一社)日本小児血液・がん学会, 2016年11月
英語 - 再発神経芽腫において獲得された片親性ダイソミーによるALK遺伝子のホモ変異(Homozygous missense mutation in ALK gene due to acquired uniparental disomy in a child with relapsed neuroblastoma)
木村 俊介; 長谷川 大輔; 代田 惇朗; 関 正史; 吉本 優里; 平林 真介; 細谷 要介; 滝田 順子; 真部 淳
日本小児血液・がん学会雑誌, 53, 4, 238, 238, (一社)日本小児血液・がん学会, 2016年11月
英語 - MEF2DおよびZNF384関連融合遺伝子陽性症例は小児B前駆細胞性ALLの中のサブグループを形成する(Incidence and clinical relevance of MEF2D- and ZNF384-related fusion genes in childhood B-cell precursor acute lymphoblastic leukemia: TCCSG L0416/0616 study)
大木 健太郎; 平林 真介; 加藤 元博; 中林 一彦; 秦 健一郎; 梶原 良介; 高橋 浩之; 福島 敬; 康 勝好; 真部 淳; 小原 明; 清河 信敬
日本小児血液・がん学会雑誌, 53, 4, 259, 259, (一社)日本小児血液・がん学会, 2016年11月
英語 - 当院における小児がんの晩期合併症に関する検討(Late effects in the children of cancer survivors: from the single institute experience)
齋藤 合; 吉本 優里; 細谷 要介; 平林 真介; 長谷川 大輔; 石田 也寸志; 浦山 ケビン; 小澤 美和; 細谷 亮太; 真部 淳
日本小児血液・がん学会雑誌, 53, 4, 275, 275, (一社)日本小児血液・がん学会, 2016年11月
英語 - メルカプトプリンによる重度の血液毒性をきたしたNUDT15ホモバリアントを有する小児急性リンパ性白血病
木村 俊介; 長谷川 大輔; 吉本 優里; 平林 真介; 細谷 要介; 吉原 宏樹; 熊本 忠史; 田中 庸一; 真部 淳
臨床血液, 57, 6, 748, 753, (一社)日本血液学会-東京事務局, 2016年06月
日本語 - Severe 6-mercaptopurine-induced hematotoxicity in childhood an ALL patient with homozygous NUDT15 missence variants.
Shunsuke Kimura; Daisuke Hasegawa; Yuri Yoshimoto; Shinsuke Hirabayashi; Yosuke Hosoya; Hiroki Yoshihara; Tadashi Kumamoto; Yoichi Tanaka; Atsushi Manabe
[Rinsho ketsueki] The Japanese journal of clinical hematology, 57, 6, 748, 53, 2016年06月, [査読有り], [国内誌]
日本語, 研究論文(学術雑誌), Thiopurine S-methyltransferase (TPMT) and nucleoside diphosphate-linked moiety X-type motif 15 (NUDT15) variants are considered to be genes responsible for severe myelotoxicity induced by 6-mercaptopurine (6MP). We report a 4-year-old girl with acute lymphoblastic leukemia, who developed the complication of severe 6MP-induced myelotoxicity due to homozygous NUDT15 variant alleles. In early consolidation therapy containing 6MP, her course was complicated by severe neutropenia (Grade 4) and chemotherapy had to be discontinued for 33 days. The 6MP dose was subsequently adjusted based on the white blood cell count. The ratios of the prescribed 6MP dose over the protocol dose in early consolidation, central nervous system (CNS) prophylaxis, re-induction, interim maintenance and maintenance therapy were 63%, 27%, 4%, 26% and 7%, respectively. Suspension of therapy was required during early consolidation, CNS prophylaxis and interim maintenance therapy. We investigated candidate genes for 6MP-associated myelotoxicity and found homozygous NUDT15 variant alleles and a heterozygous inosine triphosphate pyrophosphatase (ITPA) variant allele. In patients with homozygous NUDT15 variants, drastic reduction (less than 10%) of the 6MP dose from the protocol dose might be required not only during maintenance therapy, but also during other treatment courses containing 6MP. Screening of candidate genes at diagnosis is recommended in order to avoid serious adverse events. - 先天性QT延長症候群と局在関連てんかんを合併したKCNQ1変異を認める女児例
代田 惇朗; 小野 林太郎; 荻原 正明; 平林 真介; 横山 美奈; 白井 丈晶; 小澤 美和; 草川 功; 真部 淳
脳と発達, 48, Suppl., S369, S369, (一社)日本小児神経学会, 2016年05月
日本語 - Prevalence, clinical characteristics, and prognosis of GATA2-related myelodysplastic syndromes in children and adolescents.
Marcin W Wlodarski; Shinsuke Hirabayashi; Victor Pastor; Jan Starý; Henrik Hasle; Riccardo Masetti; Michael Dworzak; Markus Schmugge; Marry van den Heuvel-Eibrink; Marek Ussowicz; Barbara De Moerloose; Albert Catala; Owen P Smith; Petr Sedlacek; Arjan C Lankester; Marco Zecca; Victoria Bordon; Susanne Matthes-Martin; Jonas Abrahamsson; Jörn Sven Kühl; Karl-Walter Sykora; Michael H Albert; Bartlomiej Przychodzien; Jaroslaw P Maciejewski; Stephan Schwarz; Gudrun Göhring; Brigitte Schlegelberger; Annámaria Cseh; Peter Noellke; Ayami Yoshimi; Franco Locatelli; Irith Baumann; Brigitte Strahm; Charlotte M Niemeyer
Blood, 127, 11, 1387, 97, 2016年03月17日, [査読有り], [国際誌]
英語, 研究論文(学術雑誌), Germline GATA2 mutations cause cellular deficiencies with high propensity for myeloid disease. We investigated 426 children and adolescents with primary myelodysplastic syndrome (MDS) and 82 cases with secondary MDS enrolled in 2 consecutive prospective studies of the European Working Group of MDS in Childhood (EWOG-MDS) conducted in Germany over a period of 15 years. Germline GATA2 mutations accounted for 15% of advanced and 7% of all primary MDS cases, but were absent in children with MDS secondary to therapy or acquired aplastic anemia. Mutation carriers were older at diagnosis and more likely to present with monosomy 7 and advanced disease compared with wild-type cases. For stratified analysis according to karyotype, 108 additional primary MDS patients registered with EWOG-MDS were studied. Overall, we identified 57 MDS patients with germline GATA2 mutations. GATA2 mutations were highly prevalent among patients with monosomy 7 (37%, all ages) reaching its peak in adolescence (72% of adolescents with monosomy 7). Unexpectedly, monocytosis was more frequent in GATA2-mutated patients. However, when adjusted for the selection bias from monosomy 7, mutational status had no effect on the hematologic phenotype. Finally, overall survival and outcome of hematopoietic stem cell transplantation (HSCT) were not influenced by mutational status. This study identifies GATA2 mutations as the most common germline defect predisposing to pediatric MDS with a very high prevalence in adolescents with monosomy 7. GATA2 mutations do not confer poor prognosis in childhood MDS. However, the high risk for progression to advanced disease must guide decision-making toward timely HSCT. - 水痘感染の既往のない非血縁者間臍帯血移植後男児に生じた帯状疱疹
木村 俊介; 長谷川 大輔; 代田 惇朗; 松井 俊大; 吉本 優里; 平林 真介; 細谷 要介; 熊本 忠志; 真部 淳
日本小児科学会雑誌, 120, 2, 501, 501, (公社)日本小児科学会, 2016年02月
日本語 - 小児最重症再生不良性貧血に対する非血縁者間臍帯血移植
木村 俊介; 長谷川 大輔; 松井 俊大; 代田 惇朗; 石田 悠志; 吉本 優里; 平林 真介; 細谷 要介; 吉原 宏樹; 熊本 忠史; 森 愼一郎; 真部 淳
日本小児血液・がん学会雑誌, 53, 1, 21, 25, 日本小児血液・がん学会, 2016年
日本語, 最重症再生不良性貧血の治療として,重症感染症などにより早期の移植が必要にも関わらずHLA適合ドナーが得られない場合,非血縁者間臍帯血移植やHLA不適合血縁者間移植が選択肢となる.しかし,このような代替ドナーからの移植では,移植片対宿主病や生着不全の危険が高いことが問題である.我々は,感染を反復する最重症再生不良性貧血の2歳男児に対して,HLA 5/6抗原一致非血縁者間臍帯血移植を行った.総有核細胞数とCD34陽性細胞数の豊富な臍帯血を用いるとともに,前処置に低線量放射線照射を併用した.また,移植前に鉄キレート療法を行った.移植後day 20に生着が得られ,重篤な急性移植片対宿主病は認めなかった.前処置に用いた抗胸腺グロブリンの影響も疑われるサイトメガロウイルス抗原血症が5か月遷延したが,非血縁者間臍帯血移植は最重症再生不良性貧血の治療選択肢のひとつとなりうると考えられた. - ダサチニブ投与中に両側肺下胸水を認めたフィラデルフィア染色体陽性急性リンパ性白血病の男児
吉本 優里; 熊本 忠史; 木村 俊介; 平林 真介; 細谷 要介; 長谷川 大輔; 真部 淳
日本小児血液・がん学会雑誌, 52, 4, 309, 309, (一社)日本小児血液・がん学会, 2015年10月
日本語 - 融合遺伝子TCF3-ZNF384陽性B前駆細胞性急性リンパ芽球性白血病5例の臨床的特徴(Clinical characteristics of five cases of B-cell precursor acute lymphoblastic leukemia with TCF3-ZNF384 fusion gene)
平林 真介; 大木 健太郎; 清河 信敬; 谷口 明徳; 寺田 和樹; 市川 仁; 中林 一彦; 秦 健一郎; 松田 浩一; 桃沢 幸秀; 久保 充明; 松原 洋一; 福島 敬; 康 勝好; 真部 淳; 小原 明
日本小児血液・がん学会雑誌, 52, 4, 260, 260, (一社)日本小児血液・がん学会, 2015年10月
英語 - Acute megakaryoblastic leukemia with acquired trisomy 21 and GATA1 mutations in phenotypically normal children.
Rintaro Ono; Daisuke Hasegawa; Shinsuke Hirabayashi; Takahiro Kamiya; Kenichi Yoshida; Satoko Yonekawa; Chitose Ogawa; Ryota Hosoya; Tsutomu Toki; Kiminori Terui; Etsuro Ito; Atsushi Manabe
European journal of pediatrics, 174, 4, 525, 31, 2015年04月, [査読有り], [国際誌]
英語, 研究論文(学術雑誌), UNLABELLED: GATA1 mutations are found almost exclusively in children with myeloid proliferations related to Down syndrome (DS). Here, we report two phenotypically and cytogenetically normal children with acute megakaryoblastic leukemia (AMKL) whose blasts had both acquired trisomy 21 and GATA1 mutation. Patient 1 was diagnosed with transient abnormal myelopoiesis in the neonatal period. Following spontaneous improvement of the disease, leukemic blasts increased 7 months later. He received less intensive chemotherapy, and he is now 6 years old in complete remission. Patient 2 was diagnosed with AMKL at the age of 18 months. Although he received intensive chemotherapy and a cord blood transplantation, he died without gaining remission. In both cases, trisomy 21 and GATA1 mutation were detected only in leukemic blasts, but not in germline samples. Based on a literature review, we identified reports describing 14 non-DS AMKL with GATA1 mutation and acquired trisomy 21. Of those, 12 cases were diagnosed during the neonatal period, whereas the remaining 2 cases were diagnosed at the age of 22 and 31 months, respectively. CONCLUSION: These cases suggest that GATA1 mutation may cooperate with the additional chromosome 21 in developing myeloid proliferations even in non-DS patients. - 消化管出血を伴う青色ゴムまり様母斑症候群の乳児例(An infant of blue rubber bleb nevus syndrome with gastrointestinal bleeding)
平林 真介; 栗山 絢子; 石田 悠志; 吉本 優里; 細谷 要介; 吉原 宏樹; 川野 孝文; 迫田 晃子; 森田 有香; 中村 仁美; 衛藤 光; 鈴木 高祐; 末延 聡一; 長谷川 大輔; 真部 淳
日本小児血液・がん学会雑誌, 51, 4, 242, 242, (一社)日本小児血液・がん学会, 2014年10月
英語 - Clinical characteristics and treatment outcome in 65 cases with refractory cytopenia of childhood defined according to the WHO 2008 classification.
Daisuke Hasegawa; Xiaojuan Chen; Shinsuke Hirabayashi; Yasushi Ishida; Shizuka Watanabe; Yuji Zaike; Masahiro Tsuchida; Atsuko Masunaga; Ayami Yoshimi; Asahito Hama; Seiji Kojima; Masafumi Ito; Tatsutoshi Nakahata; Atsushi Manabe
British journal of haematology, 166, 5, 758, 66, 2014年09月, [査読有り], [国際誌]
英語, 研究論文(学術雑誌), This study analysed 65 children who were prospectively registered between 1999 and 2008 and fulfilled the World Health Organization 2008 criteria of refractory cytopenia of childhood (RCC). First-line therapy was determined by the treating physicians: 25 patients received immunosuppressive therapy (IST), 12 patients received haematopoietic stem cell transplantation (HSCT) and one patient received intensive chemotherapy. The remaining 27 patients were followed without treatment for more than 2 years (watch and wait; WW). In the WW group, 18 patients had stable disease without further intervention. Thirteen of 29 patients (45%) who ended up receiving IST showed response. The combination of ciclosporin and antithymocyte globulin was not shown to be superior to ciclosporin alone with regard to response rate or survival. Of 28 patients who ended up undergoing HSCT, 17 patients are alive in complete remission, whereas nine patients died mostly due to transplantation-related mortality. The 5-year overall survival for all patients was 82 ± 5%. Eight patients suffered from disease progression. Patients with monosomy 7 or multilineage-dysplasia had a significantly higher incidence of disease progression. This analysis revealed heterogeneity in the clinical course of RCC, varying from those who remained stable for long periods to those who progressed to advanced disease. - A left ventricular noncompaction in a patient with long QT syndrome caused by a KCNQ1 mutation: a case report.
Kentaro Nakashima; Isao Kusakawa; Tsuyoshi Yamamoto; Shinsuke Hirabayashi; Ryohta Hosoya; Wataru Shimizu; Naokata Sumitomo
Heart and vessels, 28, 1, 126, 9, 2013年01月, [査読有り], [国内誌]
英語, 研究論文(学術雑誌), A 5-year-old girl developed cardiopulmonary arrest after crying. From the electrocardiogram and echocardiography, a left ventricular noncompaction (LVNC) with long QT syndrome (LQT) was suspected as the cause of the cardiopulmonary arrest, and treatment with a β-blocker and a calcium antagonist was then begun. A genetic screening of LQT-related genes revealed a previously reported heterozygous KCNQ1 mutation. The association of LVNC and LQT is an extremely rare condition, and long-term treatment based on the characteristics of both disorders is required. Also, the association of cardiomyopathy and LQT could become a new clinical entity in the future. - Spliceosomal gene aberrations are rare, coexist with oncogenic mutations, and are unlikely to exert a driver effect in childhood MDS and JMML.
Shinsuke Hirabayashi; Christian Flotho; Jessica Moetter; Michael Heuser; Henrik Hasle; Bernd Gruhn; Thomas Klingebiel; Felicitas Thol; Brigitte Schlegelberger; Irith Baumann; Brigitte Strahm; Jan Stary; Franco Locatelli; Marco Zecca; Eva Bergstraesser; Michael Dworzak; Marry M van den Heuvel-Eibrink; Barbara De Moerloose; Seishi Ogawa; Charlotte M Niemeyer; Marcin W Wlodarski
Blood, 119, 11, e96-9, 2012年03月15日, [査読有り], [国際誌]
英語, 研究論文(学術雑誌), Somatic mutations of the spliceosomal machinery occur frequently in adult patients with myelodysplastic syndrome (MDS). We resequenced SF3B1, U2AF35, and SRSF2 in 371 children with MDS or juvenile myelomonocytic leukemia. We found missense mutations in 2 juvenile myelomonocytic leukemia cases and in 1 child with systemic mastocytosis with MDS. In 1 juvenile myelomonocytic leukemia patient, the SRSF2 mutation that initially coexisted with an oncogenic NRAS mutation was absent at relapse, whereas the NRAS mutation persisted and a second, concomitant NRAS mutation later emerged. The patient with systemic mastocytosis and MDS carried both mutated U2AF35 and KIT in a single clone as confirmed by clonal sequencing. In the adult MDS patients sequenced for control purposes, we detected previously reported mutations in 7/30 and a novel SRSF2 deletion (c.284_307del) in 3 of 30 patients. These findings implicate that spliceosome mutations are rare in pediatric MDS and juvenile myelomonocytic leukemia and are unlikely to operate as driver mutations. - [Prognosis of 75 patients with juvenile myelomonocytic leukemia: prospective study by MDS committee in the Japanese Society of Pediatric Hematology].
Nao Yoshida; Shinsuke Hirabayashi; Shizuka Watanabe; Yuji Zaike; Masahiro Tsuchida; Ayami Yoshimi; Atsuko Masunaga; Yoshitoshi Otsuka; Masafumi Ito; Seiji Kojima; Tatsutoshi Nakahata; Atsushi Manabe
[Rinsho ketsueki] The Japanese journal of clinical hematology, 52, 12, 1853, 8, 2011年12月, [査読有り], [国内誌]
日本語, 研究論文(学術雑誌), Juvenile myelomonocytic leukemia (JMML) is a myelodysplastic/myeloproliferative disorder of young children. Because the disease is rare and the diagnosis is difficult, a prospective registration of patients suspected of having JMML with a pathological central review have been conducted by the MDS Committee of the Japanese Society of Pediatric Hematology. Between 1999 and 2006, 75 children with JMML were enrolled and diagnosed through this system. Median age at diagnosis was 20 months (1∼85 months). Cytogenetic abnormalities were detected in 21 patients, including 11 with monosomy 7. The 5-year overall survival (OS) was 60%. Regarding the treatment, 61 of the 75 patients received stem cell transplantation (SCT). Conditioning regimen varied widely, and the source of grafts was bone marrow for 43 patients, peripheral blood for 5, and cord blood for 13. The 5-year OS after SCT was 61%. Notably, patients who received cord blood transplantation had inferior survival than those who received grafts from other sources (38 vs. 68%; P=0.03). Given better recognition of the disease, a multi-center protocol study on SCT, JMML11, is now being planned by the Japanese Pediatric Leukemia/Lymphoma Study Group. - 小児がんに罹患した子どもの同胞への心理面でのケア 弟を亡くした3歳児の事例から
武田 洋子; 小澤 美和; 相良ローゼンマイヤ みはる; 真部 淳; 小川 千登世; 長谷川 大輔; 神谷 尚宏; 平林 真介; 吉田 健一; 中島 健太郎; 山本 剛士; 細谷 亮太
小児がん, 46, プログラム・総会号, 416, 416, (NPO)日本小児がん学会, 2009年11月
日本語 - 治療中再発に対してimatinib併用Hyper-CVAD療法による第2寛解導入後にHLA一致同胞間移植を行ったPh+ALLの2例
有馬 慶太郎; 長谷川 大輔; 中島 健太郎; 吉田 健一; 平林 真介; 神谷 尚宏; 小川 千登世; 小澤 美和; 真部 淳; 細谷 亮太
小児がん, 46, プログラム・総会号, 231, 231, (NPO)日本小児がん学会, 2009年11月
日本語 - The ex vivo production of ammonia predicts L-asparaginase biological activity in children with acute lymphoblastic leukemia.
Shizuka Watanabe; Kumiko Miyake; Chitose Ogawa; Haruna Matsumoto; Kenichi Yoshida; Shinsuke Hirabayashi; Daisuke Hasegawa; Tadao Inoue; Junko Kizu; Reiko Machida; Akira Ohara; Ryota Hosoya; Atsushi Manabe
International journal of hematology, 90, 3, 347, 352, 2009年10月, [査読有り], [国内誌]
英語, 研究論文(学術雑誌), Patients with acute lymphoblastic leukemia (ALL), who develop antiasparaginase antibodies without clinical allergic reactions ("silent inactivation") during L: -asparaginase (L: -Asp) treatment, have poor outcomes. Ammonia is produced by hydrolysis of asparagine by L: -Asp. We postulated that plasma ammonia level might reflect the biological activity of L: -Asp. Five children with ALL treated according to the Tokyo Children's Cancer Study Group (TCCSG) protocol were enrolled. Plasma ammonia levels were analyzed immediately and 1 h after incubation at room temperature and "ex vivo ammonia production" was defined as increase in ammonia concentration. Ex vivo ammonia production well correlated with L: -Asp activity (r = 0.882, P < 0.01, n = 23). It always exceeded 170 microg/dL (170-345 microg/dL) in induction therapy. We found 3 patients whose ammonia production was negligible during later phases of therapy. Antiasparaginase antibody was detected and L: -Asp activity decreased in these patients. Ex vivo ammonia production is a surrogate marker of L: -Asp biological activity. - 01. 脾臓摘出術を先行して同種臍帯血移植を行った再発急性巨核芽球性白血病の1例(一般演題,第22回日本小児脾臓研究会)
長谷川 大輔; 神谷 尚宏; 吉田 健一; 中島 健太郎; 有馬 健太郎; 平林 真介; 中村 晃子; 平林 健; 松藤 凡; 小川 高史; 藤原 美恵子; 鈴木 高祐; 小川 千登世; 真部 淳; 細谷 亮太
日本小児外科学会雑誌, 45, 4, 803, 803, 特定非営利活動法人 日本小児外科学会, 2009年
日本語 - germ cell tumorに対する治療終了から3年後に発症したglioblastomaの症例
比嘉 千明; 中島 健太郎; 有馬 慶太郎; 平林 真介; 長谷川 大輔; 小川 千登世; 真部 淳; 小澤 美和; 関口 建次; 細谷 亮太; 伊藤 昌徳
小児がん, 45, プログラム・総会号, 293, 293, (NPO)日本小児がん学会, 2008年11月
日本語 - 川崎病と同時に発症したMyeloid/NK前駆細胞性急性白血病の例
有馬 慶太郎; 真部 淳; 吉田 健一; 平林 真介; 神谷 尚宏; 長谷川 大輔; 小川 千登世; 小澤 美和; 海老原 康博; 土屋 恵司; 細谷 亮太
小児がん, 45, プログラム・総会号, 301, 301, (NPO)日本小児がん学会, 2008年11月
日本語 - Picture in Clinical Hematology No. 25
平林 真介; 吉田 健一; 中島 健太郎; 有馬 慶太郎; 長谷川 大輔; 小川 千登世; 真部 淳; 細谷 亮太
臨床血液 = The Japanese Journal of Clinical Hematology, 49, 3, 139, 139, The Japanese Society of Hematology, 2008年03月30日
日本語 - 小児がん経験者のsexualityを支援するフォローアップ外来を立ち上げて
巷岡 彩子; 小澤 美和; 鈴木 麻水; 塩田 恭子; 佐藤 孝道; 有馬 慶太郎; 平林 真介; 小川 千登世; 真部 淳; 細谷 亮太
日本小児科学会雑誌, 112, 2, 278, 278, (公社)日本小児科学会, 2008年02月
日本語
- 包括的がんゲノムプロファイリング検査における小児がんの二次的所見の検討
齋藤祐介; 寺下友佳代; 平林真介; 安部樹太朗; 大浦果寿美; 長祐子; 柴田有花; 向中野実央; 藤田穂波; 有賀伸; 天野虎次; 萩尾加奈子; 山口秀; 伊師雪友; 木下一郎; 山田崇弘; 真部淳, 日本遺伝カウンセリング学会誌, 46, 2, 2025年 - 寛解導入療法中にVOD/SOSを発症した高リスク神経芽腫に対してジヌツキシマブ併用免疫化学療法を行った2歳男児例
大浦果寿美; 長谷河昌孝; 平林真介; 安部樹太朗; 大塚ゆかり; 寺下友佳代; 長祐子; 高橋遼; 河原仁守; 本多昌平; 森崇; 西岡健太郎; 橋本孝之; 高桑恵美; 真部淳, 日本小児血液・がん学会雑誌(Web), 61, 4, 2024年 - PHOTOIMMUNOTHERAPY USING ANTI-GD2 ANTIBODY FOR NEUROBLASTOMA AND OSTEOSARCOMA
Jimei Zhao; Masahiro Ueki; Kohei Nakajima; Yukayo Terashita; Shinsuke Hirabayashi; Yuko Cho; Mikako Ogawa; Atsushi Manabe, PEDIATRIC BLOOD & CANCER, 71, S5, S5, 2024年01月
英語, 研究発表ペーパー・要旨(国際会議) - IS DOSE MODIFICATION OF 6-MERCAPTOPURINE NECESSARY FOR PATIENTS WITH NUDT15 VARIANT IN EARLY INTENSIFICATION THERAPY FOR CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA?
Jimei Zhao; Masahiro Ueki; Saori Sawai; Minako Sugiyama; Yukayo Terashita; Shinsuke Hirabayashi; Yuko Cho; Ryoji Kobayashi; Yoichi Tanaka; Atsushi Manabe, PEDIATRIC BLOOD & CANCER, 71, S103, S103, 2024年01月
英語, 研究発表ペーパー・要旨(国際会議) - 小児バーキットリンパ腫による腸重積の化学療法による治療効果を経過観察し得た症例
表原里実; 表原里実; 西田睦; 工藤悠輔; 工藤悠輔; 岩井孝仁; 岩井孝仁; 砂後谷華奈; 砂後谷華奈; 渡邊千秋; 高桑恵美; 平林真介; 真部淳; 豊嶋崇徳; 豊嶋崇徳, 超音波医学 Supplement, 50, 2023年 - 当院の原発性脳腫瘍患者におけるがん遺伝子パネル検査の実情
山口秀; 茂木洋晃; 澤谷亮佑; 伊師雪友; 寺下友佳代; 平林真介; 杉山未奈子; 齋藤祐介; 木下一郎; 真部淳; 藤村幹, 日本脳腫瘍学会学術集会プログラム・抄録集, 41st, 2023年 - 多発性脳内出血で発症し急激な経過で脳死に至ったT細胞性急性リンパ性白血病(T-ALL)
長祐子; 澤井彩織; 原和也; 寺下友佳代; 杉山未奈子; 平林真介; 真部淳; 杉山拓; 方波見謙一; 浜崎和朗, 日本小児科学会雑誌, 126, 2, 2022年 - Heterozygous NUDT15 Gene Polymorphism Would Not Associate with the Severity of 6-Mercaptopurine Side Effects in Early Intensification Therapy for Childhood Acute Lymphoblastic Leukemia
Jimei Zhao; Masahiro Ueki; Saori Sawai; Minako Sugiyama; Yukayo Terashita; Shinsuke Hirabayashi; Yuko Cho; Yoichi Tanaka; Atsushi Manabe, BLOOD, 138, 2021年11月23日
英語, 研究発表ペーパー・要旨(国際会議) - Clinical Characteristics and Outcomes of Pediatric Cancer Patients who Needed Intensive Care
Ryo Nakatani; Naoki Umehara; Shoichiro Kanabuchi; Kazuyoshi Mizuki; Miho Ashiarai; Rintaro Ono; Shinsuke Hirabayashi; Yosuke Hosoya; Kevin Urayama; Daisuke Hasegawa; Atsushi Manabe, PEDIATRIC BLOOD & CANCER, 66, S39, S40, 2019年12月
英語, 研究発表ペーパー・要旨(国際会議) - Haploidentical Hematopoietic Stem Cell Transplantation for Hepatosplenic T-Cell Lymphoma
Miho Ashiarai; Daisuke Hasegawa; Akira Nishimura; Kazuyoshi Mizuki; Kaoru Yamamoto; Shunsuke Yamamoto; Rintaro Ono; Shinsuke Hirabayashi; Yosuke Hosoya; Atsushi Manabe, PEDIATRIC BLOOD & CANCER, 66, S42, S43, 2019年12月
英語, 研究発表ペーパー・要旨(国際会議) - Dasatinib-Combined Less Intensive Chemotherapy for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in Down Syndrome
Hirabayashi Shinsuke; Yamamoto Shunsuke; Yamamoto Kaoru; Yamamoto Kazuki; Aiga Saori; Daida Atsuro; Ono Rintaro; Ashiarai Miho; Nishimura Akira; Hosoya Yosuke; Hasegawa Daisuke; Manabe Atsushi, PEDIATRIC BLOOD & CANCER, 65, S97, 2018年11月, [査読有り] - Successful Inhaled Nitric Oxide Therapy for Severe Acute Respiratory Failure Due to Alveolar Hemorrhage During Induction Phase in AML M5
Ashiarai Miho; Umehara Naoki; Kuroko Yurika; Yamamoto Kaoru; Yamamoto Shunsuke; Ono Rintaro; Hirabayashi Shinsuke; Hosoya Yosuke; Hasegawa Daisuke; Manabe Atsushi, PEDIATRIC BLOOD & CANCER, 65, S55, S56, 2018年11月, [査読有り] - 腎生検にて確定診断に至った移植関連血栓性微小血管障害
宮本智史; 宮本智史; 木村俊介; 細谷要介; 長谷川大輔; 石田悠志; 代田惇朗; 松井俊大; 吉本優里; 平林真介; 藤丸拓也; 熊本忠史; 森慎一郎; 鈴木高祐; 真部淳, 臨床血液, 59, 4, 2018年 - Close Correlation Between Immunophenotype and Genetic Abnormalities in Childhood Acute Lymphoblastic Leukemia: Results from TCCSG Study L04-16
Nobutaka Kiyokawa; Takashi Fukushima; Kentaro Ohki; Motohiro Kato; Takeshi Ishibashi; Ai Yoshimi; Yuya Saito; Takahiro Aoki; Kazuki Terada; Osamu Tomita; Keiko Onda; Yoshihiro Gocho; Shinsuke Hirabayashi; Daisuke Hasegawa; Hiroyuki Takahahsi; Katsuyoshi Koh; Atsushi Manabe; Akira Ohara, PEDIATRIC BLOOD & CANCER, 64, S17, S17, 2017年11月
英語, 研究発表ペーパー・要旨(国際会議) - Multimodality Treatment for Pelvic Ewing Sarcoma
Akira Nishimura; Ayumu Arakawa; Yosuke Hosoya; Shinsuke Hirabayashi; Hiroki Yoshihara; Atsushi Kikuta; Seiichi Matsumoto; Jiro Kawamori; Daisuke Hasegawa; Tadashi Kumamoto; Chitose Ogawa; Atsushi Manabe, PEDIATRIC BLOOD & CANCER, 64, S58, S58, 2017年11月
英語, 研究発表ペーパー・要旨(国際会議) - Genetic Abnormalities and Prognosis in Pediatric B-Precursor Acute Lymphoblastic Leukemia without Conventional Genetic Abnormalities; Tokyo Children's Cancer Study Group
Kenro Ohki; Shinsuke Hirabayashi; Akinori Yaguchi; Akinori Yaguchi; Kazuki Terada; Jun Ohkubo; Norio Shiba; Motohiro Kato; Takashi Fukushima; Katsuyoshi Koh; Hayashi Yasuhide; Atsushi Manabe; Akira Ohara; Nobutaka Kiyokawa, BLOOD, 128, 22, 2016年12月
英語, 研究発表ペーパー・要旨(国際会議) - 小児造血器腫瘍の分子遺伝学の進歩 : WHO分類第4版2016改訂 (特集 小児造血器腫瘍の特色 : 分子的理解から治療開発まで)
平林 真介; 真部 淳, 血液フロンティア, 26, 11, 1561, 1568, 2016年11月
医薬ジャーナル社, 日本語 - 再発神経芽腫において獲得された片親性ダイソミーによるALK遺伝子のホモ変異
木村俊介; 木村俊介; 長谷川大輔; 代田惇朗; 関正史; 吉本優里; 平林真介; 細谷要介; 滝田順子; 真部淳, 日本小児血液・がん学会雑誌(Web), 53, 4, 2016年 - 小児血液・がん疾患に対する治療中に可逆性後頭部白質脳症症候群(PRES)をきたした3例
代田惇朗; 長谷川大輔; 山本一希; 瀬谷恵; 木村俊介; 吉本優里; 平林真介; 細谷要介; 野崎大希; 横山美奈; 荻原正明; 真部淳, 日本小児血液・がん学会雑誌(Web), 53, 4, 2016年 - 非血縁同種骨髄移植後に重症腎TMAを発症した骨髄異形成症候群の8歳女児例
宮本智史; 宮本智史; 木村俊介; 石田悠志; 代田惇朗; 松井俊大; 吉本優里; 平林真介; 細谷要介; 藤丸拓也; 長谷川大輔; 熊本忠史; 森慎一郎; 鈴木高祐; 真部淳, 日本造血細胞移植学会総会プログラム・抄録集, 38th, 2016年 - 小児最重症再生不良性貧血に対する非血縁者間臍帯血移植
木村俊介; 長谷川大輔; 松井俊大; 代田惇朗; 石田悠志; 吉本優里; 平林真介; 細谷要介; 吉原宏樹; 熊本忠史; 森愼一郎; 真部淳, 日本小児血液・がん学会雑誌(Web), 53, 1, 2016年 - Clonal Mutational Landscape of Childhood Myelodysplastic Syndromes
Emilia J. Kozyra; Shinsuke Hirabayashi; Victor Bengt Pastor Loyola; Bartlomiej Przychodzen; Axel Karow; Albert Catala; Barbara De Moerloose; Michael Dworzak; Henrik Hasle; Riccardo Masetti; Markus Schmugge; Owen Smith; Jan Stary; Marek Ussowicz; Marry M. van den Heuvel-Eibrink; Vit Campr; Rita Devito; Pascale Paepe; Miguel Hernandez-Marti; Gitte Kerndrup; Roos Leguit; Jadwiga Maldyk; Maureen OxSullivan; Ingrid Simonitsch-Klupp; Irith Baumann; Franco Locatelli; Jaroslaw P. Maciejewski; Brigitte Strahm; Charlotte M. Niemeyer; Marcin W. Wlodarski, BLOOD, 126, 23, 2015年12月
英語, 研究発表ペーパー・要旨(国際会議) - Somatic Genetic and Epigenetic Architecture of Myelodysplastic Syndromes Arising from GATA2 Deficiency
Victor Bengt Pastor Loyola; Shinsuke Hirabayashi; Sandra Pohl; Emilia J. Kozyra; Albert Catala; Barbara De Moerloose; Michael Dworzak; Henrik Hasle; Riccardo Masetti; Markus Schmugge; Owen Smith; Jan Stary; Marek Ussowicz; Marry M. van den Heuvel-Eibrink; Ester Mejstrikova; Ulrich Salzer; Michael Luebbert; Daniel Heudobler; David Betts; Jose Cervera; Gudrun Goehring; Oskar A. Haas; Olga Haus; Kyra Michalova; Francesco Pasquali; Joelle Tchinda; Nadine van Roy; Brigitte Schlegelberger; H. Berna Beverloo; Peter Noellke; Ayami Yoshimi; Franco Locatelli; Brigitte Strahm; Jaroslaw P. Maciejewski; Michael Rehli; Charlotte M. Niemeyer; Marcin W. Wlodarski, BLOOD, 126, 23, 2015年12月
英語, 研究発表ペーパー・要旨(国際会議) - 再生不良性貧血・骨髄増殖性疾患 治療関連骨髄異形成症候群44例の臨床像(Aplastic anemia and myeloproliferative disorder Clinical characteristics of 44 cases with therapy-related myelodysplastic syndrome in childhood)
長谷川 大輔; 濱 麻人; 野沢 和江; 平林 真介; 渡邉 健一郎; 土田 昌宏; 伊藤 雅文; 小島 勢二; 中畑 龍俊; 真部 淳, 日本小児血液・がん学会雑誌, 52, 4, 208, 208, 2015年10月
(一社)日本小児血液・がん学会, 英語 - 体細胞ヘテロ接合性CBL変異が長期に残存したJMML(Long-term persistence of somatic heterozygous CBL mutation in JMML)
平林 真介; 長谷川 大輔; 周尾 卓也; 村松 秀城; 坂下 一夫; 小島 勢二; 小池 健一; 真部 淳, 日本小児血液・がん学会雑誌, 52, 4, 277, 277, 2015年10月
(一社)日本小児血液・がん学会, 英語 - G-CSF製剤の在宅自己注射 (特集 内科が使う自己注射薬) -- (血液に作用する自己注射薬)
平林 真介; 真部 淳, 診断と治療, 103, 9, 1223, 1227, 2015年09月
診断と治療社, 日本語 - 頸部リンパ節炎の治療に難渋した自己免疫性好中球減少症の2例
吉本優里; 代田惇朗; 平林真介; 長沖優子; 細谷要介; 長谷川大輔; 稲井郁子; 小澤美和; 草川功; 真部淳, 日本小児科学会雑誌, 119, 2, 2015年 - 非血縁者間臍帯血移植を行った小児最重症再生不良性貧血の1例
木村俊介; 長谷川大輔; 松井俊大; 小野沙裕子; 石田悠志; 吉本優里; 平林真介; 細谷要介; 吉原宏樹; 熊本忠志; 真部淳, 日本造血細胞移植学会総会プログラム・抄録集, 37th, 2015年 - Hematopoietic Stem Cell Transplantation for Patients with Refractory Cytopenia of Childhood
Daisuke Hasegawa; Shinsuke Hirabayashi; Shizuka Watanabe; Yuji Zaike; Masahiro Tsuchida; Atsuko Masunaga; Ayami Yoshimi; Asahito Hama; Seiji Kojima; Masafumi Ito; Tatsutoshi Nakahata; Atsushi Manabe, BLOOD, 124, 21, 2014年12月
英語, 研究発表ペーパー・要旨(国際会議) - 若年性骨髄単球性白血病 (増大号特集 小児血液疾患 : よくわかる最新知見) -- (造血器悪性疾患)
平林 真介; 真部 淳, 小児科, 55, 11, 1745, 1750, 2014年10月
金原出版, 日本語 - 点鼻あるいは経口デスモプレシン製剤を用いて化学療法中の尿崩症を管理した神経下垂体部胚細胞腫 (特集 小児内分泌学の進歩2015) -- (成長・下垂体)
木村 俊介; 伊藤 純子; 吉本 優里; 平林 真介; 細谷 要介; 吉原 宏樹; 長谷川 大輔; 真部 淳, ホルモンと臨床, 62, 5, 367, 371, 2014年05月
医学の世界社, 日本語 - 急性前骨髄球性白血病M3 variantの2例
石田悠志; 松井俊大; 木村俊介; 野村耕太郎; 吉本優里; 平林真介; 細谷要介; 吉原宏樹; 長谷川大輔; 熊本忠史; 真部淳, 日本小児血液・がん学会雑誌, 51, 4, 2014年 - Characteristics of Diamond Blackfan Anemia Patients with Unknown Genetic Defect
Tamas Farkas; Joerg Meerpohl; Shinsuke Hirabayashi; Alyson MacInnes; Gunda Ruzaike; Paul Essers; Sandra Urbaniak; Jessica Moetter; Friedrich Kapp; Alexandra Fischer; Charlotte M. Niemeyer; Marcin W. Wlodarski, BLOOD, 120, 21, 2012年11月
英語, 研究発表ペーパー・要旨(国際会議) - Unexpected High Frequency of GATA2 Mutations in Children with Non-Familial MDS and Monosomy 7
Shinsuke Hirabayashi; Brigitte Strahm; Sandra Urbaniak; Axel Karow; Annamaria Cseh; Marry Van den Heuvel; Selin Aytag; Claudia Wehr; Ales Janda; Jan Stary; Henrik Hasle; Michael Dworzak; Markus Schmugge; Franco Locatelli; Barbara De Moerloose; Albert Catala; Owen Smith; Irith Baumann; Gudrun Goehring; Brigitte Schlegelberger; Charlotte M. Niemeyer; Marcin W. Wlodarski, BLOOD, 120, 21, 2012年11月
英語, 研究発表ペーパー・要旨(国際会議) - 若年性骨髄単球性白血病75例の予後 小児血液学会MDS委員会の前方視的検討
吉田 奈央; 平林 真介; 渡辺 静; 在家 裕司; 土田 昌宏; 吉見 礼美; 増永 敦子; 大塚 欣敏; 伊藤 雅文; 小島 勢二; 中畑 龍俊; 真部 淳, 臨床血液, 52, 12, 1853, 1858, 2011年12月
(一社)日本血液学会-東京事務局, 日本語 - Clinical Characteristics and Treatment Outcome of Refractory Cytopenia of Childhood (RCC): A Prospective Registration Through the Japanese Society of Pediatric Hematology
Daisuke Hasegawa; Xiaojuan Chen; Shinsuke Hirabayashi; Yasushi Ishida; Shizuka Watanabe; Yuji Zaike; Masahiro Tsuchida; Atsuko Masunaga; Ayami Yoshimi; Asahito Hama; Seiji Kojima; Masafumi Ito; Tatsutoshi Nakahata; Atsushi Manabe, BLOOD, 118, 21, 1199, 1199, 2011年11月
英語, 研究発表ペーパー・要旨(国際会議) - Analysis of Ribosomal Protein Genes Associated with Diamond Blackfan Anemia (DBA) In German DBA Patients and Their Relatives
Jessica Moetter; Mutlu Kartal; Joerg Meerpohl; Alexandra Fischer; Thorsten Simon; Sandra Urbaniaek; Shinsuke Hirabayashi; Friedrich Kapp; Peter Noellke; Christian Kratz; Charlotte M. Niemeyer; Marcin W. Wlodarski, BLOOD, 118, 21, 330, 330, 2011年11月
英語, 研究発表ペーパー・要旨(国際会議) - Mutations of the Spliceosome Complex Genes Occur In Adult Patients but Are Very Rare In Children with Myeloid Neoplasia
Shinsuke Hirabayashi; Jessica Moetter; Kenichi Yoshida; Michael Heuser; Henrik Hasle; Alexandra Fischer; Brigitte Strahm; Brigitte Schlegelberger; Irith Baumann; Felicitas Thol; Jan Stary; Franco Locatelli; Marco Zecca; Markus Schmugge; Michael Dworzak; Marry M. van den Heuvel-Eibrink; Barbara De Moerloose; Seishi Ogawa; Christian M. Flotho; Charlotte M. Niemeyer; Marcin W. Wlodarski, BLOOD, 118, 21, 1206, 1206, 2011年11月
英語, 研究発表ペーパー・要旨(国際会議) - Refractory Cytopenia In Childhood (RCC) with Normal Karyotype Is Unlikely to Progress to Advanced MDS Under a Watch and Wait Strategy
Shinsuke Hirabayashi; Brigitte Strahm; Stephan Schwarz; Marco Zecca; Markus Schmugge; Michael Dworzak; Marry van den Heuvel-Eibrink; Henrik Hasle; Barbara De Moerloose; Jan Stary; Dorota Wojcik; Ingrid Furlan; Franco Locatelli; Irith Baumann; Charlotte M. Niemeyer, BLOOD, 116, 21, 1633, 1634, 2010年11月
英語, 研究発表ペーパー・要旨(国際会議) - Noonan syndromeに合併した若年性骨髄単球性白血病(JMML)の一例
小川 高史; 久山 佳代; 平林 真介; 真部 淳; 楊 陽; 藤原 美恵子; 鈴木 高祐; 小野寺 正征; 松本 晃一; 上野 正樹; 阪本 晴彦; 長尾 俊孝; 伊藤 雅文, 日本病理学会会誌, 99, 1, 302, 302, 2010年03月
(一社)日本病理学会, 日本語 - TCCSG-L1602治療研究におけるDay8末梢血-芽球数のフローサイトメトリー測定についての評価
恩田 恵子; 平林 真介; 清河 信敬; 齊藤 正博; 森 鉄也; 福島 敬; 藤本 純一郎; 真部 淳; 康 勝好; 熊谷 昌明; 小原 明; 林 泰秀; 花田 良二; 土田 昌宏, 小児がん, 46, プログラム・総会号, 228, 228, 2009年11月
(NPO)日本小児がん学会, 日本語 - 早期強化療法中に肝中心静脈閉塞症を発症した急性リンパ性白血病の1例
吉田 健一; 長谷川 大輔; 中島 健太郎; 有馬 慶太郎; 平林 真介; 小川 千登世; 真部 淳; 細谷 亮太, 日本小児血液学会雑誌, 23, 4, 251, 255, 2009年08月31日
日本語 - 頸部絞扼事故を契機に診断した広範性発達障害の一例
山本 剛士; 笠井 恵美; 吉田 健一; 中島 健太郎; 平林 真介; 有馬 慶太郎; 小澤 美和; 真部 淳; 草川 功; 細谷 亮太, 日本小児科学会雑誌, 113, 2, 359, 359, 2009年02月
(公社)日本小児科学会, 日本語 - 1.膀胱Rhabdoid tumorの女児例(2008年度関東甲信越地区小児がん登録研究会)
比嘉 千明; 中島 健太郎; 吉田 健一; 平林 真介; 神谷 尚宏; 長谷川 大輔; 小川 千登世; 真部 淳; 細谷 亮太; 中村 晃子; 平林 健; 鈴木 高祐, 小児がん : 小児悪性腫瘍研究会記録, 46, 3, 412, 413, 2009年
がんの子供を守る会, 日本語 - Myelodysplastic Syndrome (MDS) and Myeloproliferative Disease (MPD) in Children: A Prospective Registration of 222 Cases
Shinsuke Hirabayashi; Atsushi Manabe; Shizuka Watanabe; Yuji Zaike; Masahiro Tsuchida; Atsuko Masunaga; Ayami Yoshimi; Masafumi Ito; Akira Kikuchi; Kohichiro Tsuji; Akira Ohara; Seiji Kojima; Tatsutoshi Nakahata, BLOOD, 112, 11, 926, 926, 2008年11月
英語, 研究発表ペーパー・要旨(国際会議) - Desmoplastic small round cell tumorが疑われた縦隔肉腫の乳児例
平林 真介; 青山 千晶; 伊藤 雄伍; 今村 壽宏; 加藤 格; 神谷 尚宏; 藤田 真智子; 小澤 美和; 真部 淳; 細谷 亮太; 森本 克; 松藤 凡; 鈴木 高祐; 田中 祐吉; 秦 順一, 小児がん, 45, 1, 36, 40, 2008年02月
(NPO)日本小児がん学会, 日本語
- 基本医学研究, 2024年, 修士課程, 医学院
- 基本医学総論, 2024年, 修士課程, 医学院
- 医学総論, 2024年, 博士後期課程, 医学院
- 基盤医学研究, 2024年, 博士後期課程, 医学院
- 臨床医学研究, 2024年, 博士後期課程, 医学院
- 発達障害学, 2024年, 学士課程, 医学部
- 小児健康障害論, 2024年, 学士課程, 医学部
- 統合・血液学, 2024年, 学士課程, 医学部
- 小児科学・小児外科学, 2024年, 学士課程, 医学部
■ 共同研究・競争的資金等の研究課題
- NUP98::NSD1白血病の治療抵抗性の解明と新規治療法の開発
科学研究費助成事業
2023年04月01日 - 2026年03月31日
松川 敏大; 平林 真介; 小野澤 真弘
北海道白血病ネットのヒト臨床検体からNUP98::NSD1をクローニングした。NUP98::NSD1全長が非常に長いため、全長をそのままクローニングを行うことは困難であった。まず、全長を前半部分と後半部分に分けてクローニングを行い、前半・後半部分をそれぞれPCRで増幅しベクターを制限酵素で切断した。切断部分にNUP98::NSD1の前半・後半部分を挿入し、形質転換後にプラスミド抽出を行った。それぞれの配列をサンガーシークエンスで確認すると一部に塩基置換が認められ、PCR法などによる修復を行ない、シークエンスを復元することができた。前半部分と後半部分を結合させ、全長をサンガーシークエンスで確認し、変異のないことを確認した。
当初、出来上がったNUP98::NSD1をB細胞系細胞株であるBa/F3に遺伝子導入したのちに薬剤選択により細胞株を樹立した。しかし、樹立したと思われる細胞株においてNUP98::NSD1の融合蛋白を確認できなかった。同様の手法で、他のヒト細胞株にも遺伝子導入を行ったが、同様に融合蛋白を認めることが困難であった。
薬剤耐性株は樹立できているが目的とする蛋白の発現が見られない。
この原因については判然とはしていないが、目的とする蛋白の発現が見られない以上は薬剤耐性にはなっているが何らかの原因で融合蛋白が作成できていないと考えた。
現在は、別のベクターに乗せ替えを行ってから、再度遺伝子導入を行い、今後NUP98::NSD1陽性ヒト細胞株の樹立を目指すことを目標としている。
日本学術振興会, 基盤研究(C), 北海道大学, 23K07802 - 小児・AYA世代におけるMDSの発生機序と治療戦略の解明
科学研究費助成事業
2021年04月01日 - 2024年03月31日
平林 真介; 真部 淳; 鳴海 覚志; 三谷 絹子; 小野澤 真弘
本研究は本邦の小児からAYA世代のMDSの先天性素因の同定と臨床データを合わせて統合解析を行い、発生機序の解明と治療戦略へ繋げる。成人MDSは加齢性変化の影響が大きいが、小児・AYAのMDSは遺伝的要因による造血幹細胞の脆弱性から、感染、炎症による造血ストレス環境、内因性アルデヒド代謝の違いなどにより、骨髄不全の進行と早期のクローン性造血に至ると考えられる。遺伝、環境とも多様な因子があり、未解明な部分が多い。小児科・血液内科・基礎研究を一元的に行い、先天性素因を把握する。令和3年度は症例集積と解析を進めていった。その中で、染色体異常der(1;7)(q10;p10)が、小児、AYA世代の主要な先天性素因であるGATA2異常症においてmonosomy 7に次ぐ特徴であることがわかった。これはドイツ、米国との国際共同研究に加わり、多数例の検討を行った結果であり、そのまま論文発表に至ることができた(Blood.2021;138(23):2441-2445.)。今後とも検討すべき課題はあり、国際共同研究を発展させるべく協力を継続していく。今年度も小児領域、成人領域をまたがる形で、小児科、血液内科との共同研究を開始し、遺伝子解析系とデータベースの構築に努める。また引き続き先天性素因を疑わせる核型異常に注目して、小児、AYA世代のMDS、AML症例を中心に造血転写因子の生殖細胞系列バリアントの解析を開始する。先行解析として20例の当該症例において解析系の構築を進めている。
日本学術振興会, 基盤研究(C), 北海道大学, 21K08361 - 本邦の小児~若年成人骨髄異形成症候群における先天性素因と臨床像の解明
科学研究費助成事業 若手研究
2018年04月01日 - 2021年03月31日
平林 真介
本研究は、本邦の小児から若年成人の骨髄異形成症候群において疾患の成り立ちに重要である先天性素因の同定と臨床像の解明を目的とする。平成30年度は研究対象の基盤を拡張するため、多施設で症例登録可能な研究計画書を倫理審査に諮り承認を得た。厚生労働科学研究費補助金 難治性疾患等政策研究事業「特発性造血障害に関する調査研究」(三谷班)、AMED 難治性疾患実用化研究事業「オミクス解析技術と人工知能技術による難治性造血器疾患の病因解明と診断向上に貢献する解析基盤の開発」(宮野班)との連携を進めた。家族性発症は先天性素因を疑う上で有用な手がかりであるが、家族が未発症である場合や、de novo変異による発端者の場合においてはそれらを疑うことは困難であり、小児から若年成人の骨髄異形成症候群を発症した症例の検体集積を広く行うこととした。2018年度の小児MDS治療研究会において「MDS-predisposing syndromes; オーバービューと最近の話題」のテーマで口頭発表を行い、原因疾患(種々の遺伝性骨髄不全症候群の鑑別)、臨床所見(無症状から重篤な先天形態異常まで)、血液所見(骨髄不全から白血病まで)、付加的異常(種々の染色体異常や体細胞変異)、時間経過(病状進行からreversion mosaicismなどによる自然軽快まで)などが多岐にわたる複雑な疾患群であること、これらを総合的に評価して診断治療する必要性を訴えた。また2018年度の臨床血液誌に「TP53変異と造血器腫瘍」と題して、重大ながん抑制遺伝子であるTP53遺伝子について,Leukemia-predisposing conditionの視点を中心に造血器腫瘍での状況や,TP53遺伝学的検査の課題について解説した。
日本学術振興会, 若手研究, 聖路加国際大学, 18K16128 - 小児希少症候群に合併する造血器腫瘍発生機序の解明
科学研究費助成事業 若手研究(B)
2016年04月01日 - 2019年03月31日
平林 真介; 真部 淳
多数例の検討ができない希少症候群において、造血器腫瘍の発生機序の解明はまだ途上である。本研究はMaffucci症候群、Pearson症候群などきわめて希少な症候群に合併した造血器腫瘍を対象に、網羅的遺伝子解析を行った。症候群の原因となる遺伝子異常に加えて、造血器腫瘍特異的な遺伝子異常が解明された。これらの症候群はがん素因をもち、獲得された遺伝子異常によって腫瘍の表現型が異なると考えられた。
日本学術振興会, 若手研究(B), 聖路加国際大学, 16K21376
